






























effort,! there! is! still! no! protective! vaccine.! Left! untreated,! genital! infection! can! lead! to! pelvic! inflammatory!
disease,! ectopic! pregnancy,! and! infertility.! However,! infection.induced! immunity! in! both! animal! models! and!
humans! indicates! a! strong! role! for! CD4+! Th1.biased! immune! responses.! Using! a! multi.component! vaccine!
approach!we!assessed!the!immunogenicity!and!protective!efficacy!of!novel!plasmid!DNA,!Adenovirus!5!(HuAd5)!
and! modified! vaccinia! Ankara! (MVA)! vectors! each! containing! a! major! outer! membrane! protein! (MOMP)!
transgene!and!recombinant!MOMP!protein!in!various!heterologous!prime.boost!regimens!in!BALB/c!and!B6C3F1!
mice.!!
During! the! course! of! the! prime.boost! regimens,! serum! and! vaginal! MOMP.specific! antibody! titres,!
subtypes,!avidities!and!neutralisation!abilities!were!assessed,!alongside!IFN.γ ELISpot!and!CD4+!and!CD8+!T!cell!
polyfunctionality! (IFN.γ,! TNF.α,! and! IL.2).! Regimens! were! grouped! on! the! distinct! MOMP.specific! immune!
environments!they!elicited,!with!these!regimens!taken!through! into!C.)trachomatis!vaginal!challenge!studies! in!
two!mouse!models!to!shed!light!on!the!relative!contribution!of!each!environment!to!protective!immunity.!!!!
The! DNA.HuAd5.MVA.Protein! (D.A.M.P.)! vaccine! regimen! resulted! in! a! significant! reduction! in! C.)
trachomatis!vaginal!shedding!at!day!3!post.infection!in!both!BALB/c!and!B6C3F1!mouse!strains.!This!significant!
reduction! was! lost! when! D.A.M.P.! vaccinated! mice! were! depleted! of! their! CD4+! T! cells! prior! to! challenge,!





leading! cause!of! infectious!blindness! in! the!world.!Recently,! Kari!et) al.! revealed! serum!anti.MOMP!antibodies!
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The! use! of! vaccines! has! been! instrumental! in! the! prevention! and! control! of!
infectious! disease! and! remains! one! of! the! most! cost.effective! public! health!
interventions.! ! In! the! 1790s,! Edward! Jenner! was! the! first! to! demonstrate! that!
inoculation!with!cowpox!virus!could!confer!protection!against!smallpox! in!man![1].!
To! date! smallpox! is! the! only! human! infectious! disease! to! be! eradicated! through!
vaccination,! closely! followed!by!poliomyelitis!which!has!had! it’s! incidence! reduced!
by!>99%![2].!Though!not!eradicated,!vaccination!still!controls!and!reduces!the!global!





the! establishment! of! an! effective! immune! response! requiring! both! the! innate! and!
adaptive!arms!of! the! immune! system.!Most! current! licensed!vaccines! (Hepatitis!B,!




malaria! and! HIV,! it! is! likely! that! vaccine! induced! protection!may! require! effective!
!17!
engagement! of! both! the! humoral! and! cellular! arms! of! the! immune! system.! In!
addition! to! the! humoral! and! cellular! arms! of! immune! responses! the! system! has!




Once!barrier! immunity! is!breached,! the! innate! immune!system! is! the! first!point!of!








or! cells! downregulating! their! major! histocompatibility! complex! (MHC)! class! I!




immune! system,! such!as!gene!arrangement!of! their!T! cell! receptor! (TCR).! ! Though!
!18!
they!do!not! recognise!MHC!presented!antigens,! they!do! release! cytokines! such!as!
IFN.γ![8].!!
Dendritic!cells,!macrophages!and!neutrophils!are!the!phagocytic!cells!of! the! innate!
immune! system.! Upon! interaction! with! various! cell! surface! receptors! (CD205,!
macrophage! mannose! receptor,! scavenger! receptors)! they! internalise! pathogens,!





pathogens!are! recognised!by!pathogen!recognition!receptors! (PRRs),!which! lead!to!
the! activation! of! the! innate! immune! system! through! distinct! signaling! pathways.!
Several! PRRs! are! expressed!by! innate! immune! cells! such! as! the! Toll.like! receptors!
(TLRs),!NOD.like!receptors!(NLRs),!and!RIG.like!receptors!(RLRs)![10].!Nine!functional!
TLRs! have! been! discovered! in! humans! (and! 11! in!mice)! and! are! broadly! classified!
according!to!their!ligands![11].!TLRs!1,!2,!4!&!6!recognise!lipids!and!are!expressed!on!
the! cell! surface! of! many! cells! of! the! immune! system,! whereas! TLRs! 3,! 7,! 8! &! 9!
recognise!nucleic!acid!and!are!expressed!in!endosomal!compartments.!TLR!agonists!
have! been! extensively! used! in! adjuvant! development! [12]! and! are! discussed! in!
1.3.4.1.!!









Dendritic! cells! (DCs)! are! professional! antigen! presenting! cells! (APCs)! that! act! as!
messengers! between! the! innate! and! the! adaptive! immune! systems.! Therefore! the!
activation! of! these! cells! is! essential! in! generating! a! protective! immune! response.!!
DCs! circulate! in! peripheral! tissues! including! the! dermis! and! epidermis!where! they!
endocytose! antigen,! process! it! for! display! on!MHC!molecules! before!migrating! to!
secondary!lymphoid!organs!where!they!display!antigen!to!T!cells![15].!!DCs!can!also!
present!antigen!to!B!cells!in!high!endothelial!venules!(HEVs)![16].!Once!activated!by!
PAMPs,! DCs! mature! and! secrete! cytokines! such! as! IL.12! and! IL.23,! further!
modulating!the!immune!response!induced![17].!Pattern!recognition!receptors!(PRRs)!
expressed!on!DCs! include!Toll.like!receptors! (TLRs),!NOD.like!receptors! (NLRs),!and!
RIG.like!receptors!(RLRs)![10].!
Plasmacytoid! dendritic! cells! (pDC)! are! a! subset! of! dendritic! cells,! constituting! 0.2.
0.8%!of!the!peripheral!cell!blood!population!in!humans![18].!These!cells!express!TLR7!
and! TLR9! and! play! a! major! role! in! antiviral! immunity! by! rapidly! producing! large!













presented! by! APCs! (B! cells! and! DCs)! on! MHC! molecules! in! the! presence! of! co.
stimulatory!signals.!They!are!distinguished!from!other!lymphocytes!by!the!presence!
of! a! T.cell! receptor! (TCR),! and! are! named! as! such! due! to! their! development! and!
maturation! in! the! thymus.! CD4+! T! cells! recognise! exogenous! antigen!displayed!on!
MHC!class!II!molecules!of!the!APC,!while!CD8+!T!cells!recognise!endogenous!antigen!
degraded! in! the!cells!cytoplasm!which! is! then!displayed!on!MHC!class! I!molecules.!
However,! there! is!also! the!phenomenon!of! cross.presentation! in!which!exogenous!
antigen! is! loaded!onto!MHC!class! I!molecules! resulting! in! the!activation!of!CD8+!T!





CD4+! T! cells! act! through! the! recruitment! and! activation! of! target! cells! mainly!
through!the!secretion!of!cytokines!and!chemokines.!!Naïve!conventional!CD4+!T!cells!
have!at!least!4!distinct!fates!depending!on!the!pattern!of!signals!they!receive!during!
their! initial! interaction!with!antigen:!Th1,!Th2,!Th17,!and!T! regulatory!cells.!Within!
the! scope!of! this! thesis! and! relevancy! to! chlamydia! vaccination,! only! Th1!and!Th2!
induction!has!been!measured!and!investigated.!
Under! the! stimulation! of! IFN.γ! and! IL.2,! naïve! CD4+! differentiate! into! Th1! T! cells!
through! the! expression! of! the! transcription! factor! T.bet! [20].! Th1! cells! mediate!
immune! responses! against! intracellular! pathogens.! They! principally! secrete! IFN.γ!
and! tumor! necrosis! factor! (TNF).α,! with! IFN.γ! being! important! in! activating!
macrophages! to! increase! their!microbicidal! activity,! recruiting! NK! cells,! as! well! as!
promoting!opsonising!antibody!protection!and!isotype!class!switching!of!B!cells![21].!
Th2.type! cells! are! differentiated! in! the!presence!of! IL.4! through! the! expression!of!
the! transcription! factor! GATA.3! [22].! Th2! cells! mediate! the! activation! and!
maintenance!of!the!humoral!immune!response!by!secreting!IL.4,!IL.5,!IL.9,!IL.10,!IL.








displayed! on! MHC! class! I! of! an! infected! cell,! CD8+! T! cells! secrete! the! pro.
inflammatory! cytokines! IFN.γ! and! TNF.α,! recruiting! phagocytes! to! the! site! of!
infection.! !Furthermore,!CD8+!T!cells! induce!the!death!of!their! target!cells! through!
the! direct! release! of! perforin! and! granzymes.! Perforin! mediated! membrane! pore!
formation!allows!granzymes!to!enter!the!target!cell’s!cytoplasm!where!they!trigger!
the! caspase! cascade! eventually! leading! to! apoptosis.! Another! way! apoptosis! is!










have! innate.like! properties,! not! circulating! through! lymph! nodes,! and! can! be!




cytokine!environment,! the!B! cells! can!undergo!class! switching! to!produce! isotypes!
IgG,!IgA!and!IgE.!!
!
B! cells! can! further! undergo! somatic! hypermutation! and! clonal! selection! in! an!
organised! germinal! centre! to! produce! high! affinity! antibodies.! Following! contact!
with!antigen!in!secondary!lymphoid!organs,!B!cells!migrate!to!the!interface!of!the!T!
cell! zone!within! the!B! cell! follicle.!Here!antigen!bound! to! the!BCR! is! taken!up!and!
processed!before!being!presented!to!T!cells!on!MHC!class!II![26].!T!cells!recognising!
this! peptide.MHC! complex! secrete! IL.6! and! IL.21! and! synthesise! CD40L,! which!
interacts! with! CD40! on! the! B! cell! to! initiate! B! cell! proliferation! and! affinity!
maturation,!and!finally!to!effect!maturation!of!the!activated!B!cell!into!an!antibody!
secreting! cell.! !Activated!B! cells! can!produce!either! short.lived!plasma!cells!or! can!
enter!the!germinal!centre!reaction!to!produce!long.lived!plasma!cells!and!memory!B!
cells! (mBCs).! These!mBCs! can! redifferentiate! back! into! antibody! secreting! plasma!
cells! after! re.encountering! antigen! and! thus! make! up! humoral! immunological!
memory!that!provides!long.term!immunity.!
The!circulation!of!B!cells!and!their!entry!and!retention!in!secondary!lymphoid!organs!
is! dependent! upon! adhesion! molecules! and! chemokine! receptors! [27]! [28].! The!
expression! of! LFA.1! and! VLA.4! permit! entry! into! the! lymphoid! tissue,! with! the!
chemokine!receptors!CXCR5!and!CCR7!directing!localisation!within!the!tissue.!CXCR5!
is! expressed!on! all!mature!B! cells! and!mediates! the!B! cell!migration! to! follicles! in!
response!to!CXCL13.! If! the!B!cell!does!not!encounter!a!cognate!antigen! it!exits!the!
!24!
lymphoid!organ!in!response!to!the!sphingosine.1.phosphate!(S1P)!molecule,!but!on!
antigenic! encounter! the! B! cells! are! retained! in! the! lymphoid! organ! due! to! the! up!
regulation! of! CCR7! [29].! The! ligands! for! CCR7! (CCL19! and! CCL21)! attract! antigen.
activated!B!cells!to!the!T!cell!zone!where!cognate!T!cell.B!cell!interactions!occur,!and!
later! the! chemokine! CXCL12! promotes! the!migration! of! plasmablasts! to! the! bone!
marrow!where!they!develop!into!long.lived!plasma!cells![30].!!
Antibodies! have! a! variety! of! effector! functions.! These! include! neutralisation,!
complement! activation,! as! well! as! initiating! phagocytosis! in! macrophages! and!








spleen,! lymph! nodes! and! bone! marrow! of! the! systemic! system! [31].! ! Mucosal!
epithelial! cells! provide! both! a! physical! barrier! and! a! site! for! innate! immunity.!
Physical!barriers!include!the!presence!of!mucus!secreted!from!goblets!cells!and!the!





cellular!basis!of! immune!responses! in! the!gastrointestinal!and! female! reproductive!
tracts! involves! the!migration!of! lymphocytes! from!these!mucosal! inductive!sites! to!
the! effector! tissues! via! the! lymphatic! system.! The! mucosa.associated! lymphoid!
tissue! (MALT)! network! including! the! gut.associated! lymphoid! tissues! (GALT)! and!
nasopharyngeal.associated!lymphoid!tissues!(NALT)!provides!the!source!of!memory!
T!and!B!cells!which!then!move!onto!effector!sites![34].!The!MALT!also!contains!APCs,!
including! DCs,! which! can! carry! antigen! to! mesenteric! lymph! nodes! to! initiate!
mucosal!T!and!B!cell!responses,!while!mucosal!homing!receptors!on!activated!T!cells!
direct!these!migrating!cells!to!the!mucosal!lamina!propria![35].!!
The! lamina! propria! regions! of! female! reproductive! tract! contain! antigen.specific!











Issues!with! the!safety!profile!of! live!vaccines,! the!weak! immunogenicity!of! subunit!
vaccines!and!immunisation!failure!due!to!poor!patient!compliance!to!booster!doses!
are!a!few!of!the!reasons!which!necessitated!the!development!of!a!new!generation!of!
vaccines! to! promote! effective! immunisation.! Attempts! have! been!made! to! deliver!
vaccines! through! carriers! such! as! liposomes! or! nanoparticles! or! ISCOMs,! as! they!
spatially! and! temporally! control! antigen! presentation! to! the! immune! system.! This!
allows!reduced!doses!of!weak!immunogens!to!still!stimulate!immune!responses![40].!
!
In! some! instances! the! immunologically! protective! immunity! may! be! complex! and!
necessitate!the!induction!of!strong!cellular!immunity!rather!than!a!threshold!titre!of!
neutralising! antibodies.! To! that! end,! replication.deficient! viral! vectored! vaccines,!




There! has! also! been! increasing! recognition! that! such! delivery! platforms! pose!
numerous!advantages,! including! relative!ease!of! generation,! genetic!manipulation,!
scale.up! and! manufacture;! capacity! for! relatively! large! inserts! and! potential! for!






A!significant!advantage!of!DNA!vaccines! is! their!ability! to!evoke!both!humoral!and!




to! naive! T! cells.! Here,! activated! antigen.presenting! CD4+! T.helper! cells! activate! B!
cells,! resulting! in!both!arms!of! the! immune! system! targeting! the!plasmid.encoded!
antigen! [47].! The! vaccine! protein! can! also! be! taken! up! by! scavenger! cells! such! as!
macrophages!and!DCs!and!presented!without!cross.presentation!on!the!exogenous!
Class! II! pathway.! DNA! vaccines! can! encode! multiple! immunogenic! epitopes,! and!
their! construction! can! be! rapid,! cheap! and! large.scale,! making! them! a! serious!
alternative!vaccine!platform.!!!!
!
The! intramuscular! route! is! the! most! common! route! of! immunisation! for! DNA!
vaccines,! with! myocytes! being! the! predominant! cell! type! transfected! [48].!
Electroporation! is! among! the! most! effective! preclinical! delivery! systems! for! DNA!
vaccines! to! increase! the! transfection!efficiency!of! target!cells.! !Electroporation!can!
involve! delivering! an! electric! current! at! the! same! time! as! the! DNA! injection,! or!
!28!
involve!penetrating!probes! that! target! the!muscle! to!deliver! an!electric!pulse.! The!
current!hypothesis! is! that!electroporation! forms! transient!membrane!pores!due! to!
the! transmembrane! voltage,! and! this! membrane! destabilisation! facilitates! the!
movement!of!macromolecules!in!the!extracellular!medium!to!the!intracellular!milieu,!




A! few! potential! concerns! of! DNA! vaccination! include! the! theoretical! risks! of!








Recombinant! viral! vectors! have! also! been! explored! as! vaccine! delivery! platforms,!
particularly!aimed!at! inducing!strong!T!cell!responses!through!their!direct! infection!




Adenoviruses! are! dsDNA! viruses! (34.43! kb)! belonging! to! the! Adenoviridae! family.!
They!are!an!attractive!vaccine!platform!due!to!their! thorough!characterisation!and!
ease! of!manipulation! [57].! For! vaccine! vector! use,! Adenoviruses! have! been!made!
replication.defective! for! human! cells! by! deleting! the! E1! and! E3! regions.! The! E1!
region! codes! for! viral! proteins! essential! for! the! initiation!of! viral! replication,!while!
the!E3! region! is! involved! in! immunomodulation! [58]! [59],! and! such!deletions!have!
allowed!for!the!insertion!of!up!to!~6!kb!of!foreign!DNA!into!the!viral!vector.!
!
The! majority! of! Adenovirus! vectored! vaccines! have! been! based! on! the! human!
serotype!5!adenovirus! (HuAd5),!with! this!vector!able! to! induce!strong!B!and!T!cell!
responses!against!multiple!different!antigens![60]![61]![62]![63].!HuAd5!has!a!broad!
tropism,! infecting! a! variety! of! dividing! and! non.dividing! cells! through! the!
Coxsackievirus! and! adenovirus! receptor! (CAR),! and! can! be! applied! systemically! as!
well!as!through!mucosal!surfaces.!Their!thermostability!and!ability!to!be!produced!to!
high! titres! under! GMP! conditions! has! facilitated! their! clinical! use! and! they! have!
already! been! used! in! 5! independent! HIV! vaccine! trials,! proving! to! be! safe! and!
immunogenic! in! humans! [64]! [65]! [66]! [67].! The! vector’s! safety! was! thrown! into!
doubt! following! an! HIV! trial! in!which! a! non.significant! trend! for! an! increased! HIV!
infection! rate! in! immunised! volunteers! who! were! seropositive! for! HuAd5! before!
vaccination!was!found![68].!Further!analyses!have!revealed!no!durable!relationship!




HuAd5! has! been! an! invaluable! tool! in! pre.clinical! vaccine! screenings,! yet! the! high!
prevalence! of! pre.existing! immunity! to! HuAd5! within! the! human! population! has!









genus!allowed! the!vaccinia! virus! to!be!used! to! vaccinate!millions!of!people!during!
the!WHO’s! smallpox!eradication!campaign! [72].!However,!as! vaccinia! is! replication!
competent,!safety!concerns!resulted!in!the!development!of!replication!incompetent!
vaccinia!virus.!The!virus’!570!passages! through!chick!embryo! fibroblast! cells! (CEFs)!







MVA! has! conserved! the! ability! to! activate! robust! cellular! MHC! class! I.! and! II.
restricted! CD8+! and! CD4+! T! cell! responses! against! recombinant! antigens.! MVA!
vectors! have! never! been! used! for! vaccination! against!Chlamydia) trachomatis,! but!
have!been!successfully!used!to!target!infectious!diseases!including!malaria,!HIV!and!
TB! [74],! [75],! [76].! MVA! expressing! the! Mycobacterium! tuberculosis! antigen! 85A!
(MVA85A)!has!been!used!in!Phase!I/II!clinical!trials!as!a!boost!to!the!BCG!prime,!with!




Recombinant! protein! vaccines! typically! consist! of! protein! antigens! produced! in! a!
heterologous! expression! system,! such! as! bacteria,! yeast! or! eukaryotic! cells.!
Recombinant! protein! vaccines! are! based! on! the! concept! that! humoral! immune!
responses! mounted! towards! an! infection! are! often! targeted! to! regions! on! the!
surface! of! protein! antigens,! known! as! epitopes.! These! immunogenic! proteins! are!
then! expressed! using! heterologous! expression! systems.! Vaccinating! with! just! the!
most! immunogenic! protein(s)! induces! a! more! targeted! immune! response! and!




Based! on! their! composition,! recombinant! protein! vaccines! predominately! invoke!
humoral! immune! responses!and!antibody.based! immunity.! There!are!a!number!of!
successful,! commercial! recombinant! protein! vaccines! where! antibody! based!





Adjuvants,! or! “the! immunologist’s! dirty! little! secret”! [80],! are! formulations! of!
chemical! compounds! or! molecules! added! to! recombinant! protein! vaccines! to!
enhance!their! immunogenicity!or!to!alter!their! immunogenic!profile.!Adjuvants!are!
added! to! recombinant! proteins! as! they! lack! the! intrinsic! immunogenic! properties!
found!in!live,!attenuated,!killed!whole!organism!or!even!virally!vectored!vaccines.!In!
addition! to! directing! immune! responses! against! target! antigens,! adjuvants! can!
prolong!vaccine! induced! immune! responses,! as!well! as! increasing! the!breadth!and!
quality!of!immune!responses!they!induce![81],![82],![83].!!
!
Two! specific! adjuvants! are! used! in! this! thesis:!MF59! and!monophosphoryl! lipid! A!
(MPLA).!MF59!is!the!only!purely!emulsion.based!adjuvant!currently!licensed!for!use!
in! humans! and! is! an! oil.in.water! emulsion! consisting! of! squalene,! produced! by!
!33!
Novartis,!and!used!in!Europe!in!an!influenza!vaccine![84].!!It!has!been!shown!to!lead!
to! a! broader! more! balanced! IgG1/IgG2a! response! in! mice! and! when! used! as! the!
adjuvant!in!a!Phase!1!H5N1!influenza!vaccine!trial!resulted!in!the!persistence!of!the!
protective!antibody!response![85].!MF59!was!thought!to!function!through!an!antigen!




Monophosphoryl! lipid!A! (MPLA)! is! the!only! toll.like! receptor! (TLR)!agonist! licensed!
for! use! in! humans.!MPLA! is! an! agonist! for! TLR4,! and! is! a! part! of! the! Fendrix!HBV!
vaccine! produced! by! GSK.! All! TLRs! apart! from! TLR! 3! signal! through! the! adaptor!
molecule!MyD88,!whereas!TLR3!signals!through!TRIF.!TLR!4!is!unique!in!its!ability!to!
signal!through!both!adaptor!molecules.!MPLA!is!a!modified!analogue!of!the!Lipid!A!
moiety!of! Lipopolysaccharide! (LPS)!which! is! itself! too! toxic! for!use! in!humans,!and!




Single! immunisations!or! sequential! immunisations!utilising! the! same! vaccine!often!

















or!blinded! [93].!Genital! infections!by!C.) trachomatis)are!of!notable!global!concern.!
The!WHO!rates!genital!chlamydial!infections!as!the!most!common!bacterial!sexually!
transmitted!disease! (STD)!worldwide,!with!over! 90!million!of! the! 500!million! total!
yearly!global!cases!of!STDs!being!C.)trachomatis![94].!Economically,!in!the!USA,!over!




C.) trachomatis! infects! the! single.cell! columnar! epithelial! cells! of! the! endocervix! of!
women!and!the!urethra!of!men.!Within!these!epithelial!cells,!Chlamydia!undergoes!a!
unique!biphasic!developmental! cycle! (Figure!1.1).! ! The! infectious!elementary!body!
(EB)! is! endocytosed! by! mucosal! epithelial! cells! before! being! surrounded! by!
endosomal! membranes! to! form! an! inclusion.! Within! this! inclusion,! the! EB!
differentiates! into! the!more!metabolically! active! reticulate! body! (RB),! which! then!
divides! by! binary! fission.!Within! 40.48! hours! the! RBs! redifferentiate! into! infective!
EBs,! before! inclusion! exocytosis! releases! the! EBs! to! infect! neighbouring! cells.!
Intracellular!RBs!can!form!a!non.replicating!persistent!state!if!under!stresses!such!as!
penicillin!exposure,!but!revert!after!the!removal!of!the!stress.!
Sexually!transmitted!C.)trachomatis! infection! is!an! important!public!health!concern!
due!to!its!adverse!effects!on!reproduction.!Pelvic!inflammatory!disease!(PID),!ectopic!

























Adapted! from!Robert!C.!Brunham!&! J.!Rey.Ladino! [99].! !C.) trachomatis! resides!within!a! specialised!
vacuole! termed! an! ‘inclusion’! which! provides! a! permissive! environment! for! the! replication! of! C.)
trachomatis.!Within! the! inclusion,! the! EB! differentiates! into! the! RB!which! divides! by! binary! fission!
before! dedifferentiating! back! into! EBs.! These! EBs! are! released! from! the! inclusion! to! infecting!
neighbouring!cells!!
!37!
Although! early! detection! of! infection! can! lead! to! successful! treatment! with!
antibacterial! agents! (in! particular! doxycyclines),! the! high! proportion! of!
asymptomatic! infections! (70.90%! in! women,! and! 30.50%! in! men)! often! result! in!
severe!and!sometimes!irreversible!complications!presenting!as!the!first!symptoms!of!
an!infection![100]![101].!Up!to!40%!of!untreated!chlamydial!genital!infections!lead!to!
PID,! and! overall! 11%! of! women! with! PID! develop! TFI! and! 9%! develop! ectopic!
pregnancies![102].!C.)trachomatis)screening!and!treatment!programs!have!been!set!
up!in!the!United!Kingdom,!the!United!States,!Australia,!Canada,!Finland,!Norway!and!
Sweden,!yet! in!all!of!these!countries!Chlamydia)rates!have!appeared!to! increase! in!
the! face! of! these! programs! [103].! These! increased! rates! could! be! due! to!
improvements! in!Chlamydia) testing! technology,! but! another! hypothesis! is! that! by!
identifying!and!treating!chlamydial!infections!early,!the!infected!individuals!may!not!
develop! protective! immunity! to! re.infection.! This! “arrested! immunity! hypothesis”!
suspects! that! those! treated! are! still! susceptible! to! subsequent! infection,! and! they!
likely!rejoin!their!previous!sexual!networks!and!become!reinfected![103].!Therefore,!
of! the! different! prevention! and! control! strategies! being! developed! against!
Chlamydia,!the!current!medical!opinion!is!that!immunisation!is!likely!to!be!the!most!







required! for! protection! against! Chlamydia.! To! analyse! the! innate! and! adaptive!
responses! to! infection!with!C.) trachomatis,! the!mouse!model! of! vaginal! infection,!
using!the!murine!chlamydial!strain!C.)muridarum,!has!often!been!used.!C.)muridarum)
is! commonly! used! as! an! analogue! to! C.) trachomatis,! though! there! are! notable!
differences!in!their!pathology.!C.)muridarum)is!naturally!a!gut!pathogen!of!mice,!not!
typically! a! genital! infection,! and!mice! usually! clear! experimental! genital! infections!
with! this! strain!within! 4!weeks,! whereas!C.) trachomatis) infections! in! humans! can!
persist!for!months!or!years![104].!Due!to!these!pathological!differences,!we!will!use!
C.) trachomatis) in! the!mouse!model! as!demonstrated!by!Olsen!et)al.,! (2010)! [105],!
Peterson!et!al.,!(1999)![106]!and!Ramsey!et!al.,!(1999)![107].!Oculogenital!serovars!of!
C.) trachomatis) can! successfully! infect! the! murine! genital! tract,! with! the! resulting!




genital! tract! mucosa! [99].! T! cells! are! known! to! be! key! mediators! of! protection!
against! Chlamydia) infection.! Nude! mice! were! shown! to! be! unable! to! control!
infection,! indicating! the! need! for! T! cell! mediated! immunity! [109].! Furthermore,!
depletion! of! either! CD4+! or! CD8+! T! cells! leads! to!more! severe! primary!Chlamydia)




in! nude! mice! while! CD4+! Th2! clones! did! not! induce! protection! [112],! [113].! The!
adoptive! transfer! of! Chlamydia) specific! CD8+! T! cells! also! conferred! protection!
against! Chlamydia) challenge,! although! it! was! not! as! effective! as! CD4+! T! cells,!
indicating!a!stronger!role!for!CD4+!T!cells.!Th1!cytokines,!specifically!IFN.γ!and!IL.12!





The! role!of!humoral! immunity! in!C.) trachomatis)protection! is! less!clear.! Infected!B!
cell! deficient! mice! develop! immunity! to! Chlamydia) genital! infection! normally,!
indicating!B!cells!are!not!necessary!for!the!generation!of!protective!immunity![116].!
However! C.) muridarum) pre.infected!mice! depleted! of! CD4+! and! CD8+! T! cells! are!
resistant! to! secondary! Chlamydia) genital! infection,! suggesting! that! optimally!
matured!B!cells!and!antibodies!can!be!protective!against!a!secondary!infection![117].!
In! addition,! passive! immunisation! of! Chlamydia) infected! mouse! serum! to! B! cell!
deficient!mice!depleted!of!CD4+!T!cells!yielded!protection! to!C.)muridarum)genital!
infection![118].!Taking!these!data!into!account,!it!is!currently!believed!that!humoral!





Mice! are! the!most! commonly! used! animals! in! genital! chlamydia! infection! studies.!
They! are! commonly! adopted! due! to! their! ease! of! handling,! low! cost,! and! the!




closely! resembling! an! acute! genital! C.) trachomatis! infection! in! women! [120].! The!
infection! ascends! to! the! uterine! horns! and! oviducts! resulting! in! hydrosalpinx! and!
infertility,!which!are!also!usual!post.infection!pathologies! in!women![122]! [123].! In!
contrast,!intravaginal!inoculation!with!C.)trachomatis!in!mice!results!in!a!mild!genital!
tract! infection! that! resolves! quickly! and! is! unable! to! ascend! the! genital! tract.!




and! pathogenesis! in! women! [125].! The! similarity! in! pathogenesis! following! C.)
muridarum! infection! and! women! with! post.chlamydial! sequelae! makes! the! C.)
muridarum!model!useful!for!the!study!of!Chlamydia!pathogenesis,!but!as!it!doesn’t!




and! the!outcome!of! infection! in! the!majority! of!women!–! the! asymptomatic,! self.









lived;! again! analogous! to! humans! [132].! However,! the! lack! of! Guinea! pig! specific!
reagents! makes! studying! Guinea! pig! immunology! difficult! and! restrictive! in!
comparison!to!the!murine!models.!! 
 
The! pig! has! been! investigated! as! a! large! animal! model! for! the! studying! of! C.)
trachomatis! genital! infections.! The!majority! of! genes! expressed! in! porcine! female!
reproductive!tissues!have!been!found!to!be!expressed!in!human!genital!tissues![133],)
with!pigs!furthermore!naturally!susceptible!to!four!Chlamydial!species!(though!not!C.)






genital! reproductive! tract! anatomies! and!physiologies! to!human!women,! including!
the!vaginal!microflora!and!their!28.30!day!menstrual!cycle![135]. Furthermore,!pig.
tailed! macaques! are! naturally! susceptible! to! genital! tract! infections! with! human!
strains!of!C.)trachomatis,!not!requiring!any!hormonal!pretreatment![136].!Repeated!
C.)trachomatis!infections!can!cause!tubal!scarring!and!tubal!obstruction!in!pig.tailed!









or! live,! attenuated! whole! organism! preparations.! Though! offering! a! degree! of!
protection,!their!high!cost!and!complexity!of!production!along!with!the!presence!of!
immunopathological! antigens! have! hampered! their! clinical! use.! These! first!





The! first! vaccines! used! against! Chlamydiaceae! were! live! attenuated.! Strains! were!
attenuated! by! the! passaging! of! a! wild.type! strain! in! different! cell! types! or! by!
chemical!mutagenesis,!inducing!mutations!resulting!in!avirulent!Chlamydia.!The!live!








the!use!of! live!attenuated!chlamydia!against!genital!C.) trachomatis! infection.!Mice!
intranasally!immunised!with!viable!C.)trachomatis!serovar!E!exhibited!significant,!but!
not!complete!protection!upon!a!vaginal!challenge![106].!In!addition,!mice!vaccinated!






killed!Chlamydia,!with! inactivation!by!heat!or! chemical! (formalin)! treatment.! Their!
major!disadvantage!is!their!inability!to!replicate,!thus!requiring!revaccination!and!the!
use!of!adjuvants.!Their!replication!deficiency!also!makes!them!poor!inducers!of!cell.
mediated! immunity!though!capable!of! inducing!humoral! immunity![141].! ! In!a!rare!
study! on! inactivated/killed! chlamydia! vaccines! against! genital! C.) trachomatis!
infection,!neither! intranasal!nor! intraperitoneal! immunisation!with!1x106! IFU!of!UV!
inactivated! C.) trachomatis! serovar! E! elicited! protection! against! genital! infection!
[106].!!!
The! 1960s! saw! unsuccessful! attempts! to! develop! inactivated! and! live! vaccines!
against!trachoma!in!both!human!and!nonhuman!primates!models![142]![143]![144].!
Although!these!vaccines!were!capable!of!reducing!disease!in!some!individuals,!they!
did! enhance! disease! in! others! resulting! from! an! enhanced! delayed.type!
hypersensitivity! (DTH)! response.! Following! these! studies,! the! use! of! whole!




Subunit! vaccines! are! safer,!with! the! inability! to! revert! to! a! virulent! form,! and! can!





(MOMP)!following! its! identification!as!a!structurally!and! immunologically!dominant!
protein!accounting! for!60%!of! the!chlamydial!outer!membrane! [146].! !However! its!
efficacy! as! a! vaccine! candidate! is! chequered! throughout! the! literature.! Chlamydial!
outer! membrane! complex! (COMC)! preparations! of! C.) muridarum! induced!
significantly!protective! immunity! in!mice!against!a!genital! challenge,!while!purified!
MOMP! alone! preparations! did! not! [147].! However,! the! same! research! group!
subsequently! immunised! with! a! purified! and! refolded! preparation! of! MOMP!
adjuvanted!with! Freund’s! that! did! provide! a! significant! level! of! protection! in!mice!
against!genital! challenge! [148].! ! Studies!have! revealed! that! some!preparations!can!
induce!more!protection! than!others,! probably!due! to! the!differences! in! extraction!
methods,!which!may!influence!conformationally!important!epitopes!of!MOMP.!Due!
to! their! high! expense! and! the! difficulty! in! growing! chlamydia! in! bulk,! purified!
chlamydial!proteins!are!not!commercially!viable!vaccine!candidates.!!This!has!lead!to!
interest! in! recombinant! MOMP! (rMOMP)! preparations! made! in! prokaryotic!
expression! systems.! Transcutaneous! immunisation! with! rMOMP! adjuvanted! with!
cholera! toxin! and! CpG! resulted! in! enhanced! clearance! of! C.) muridarum) in! mice!
following!genital!challenge![149].!In!addition!C.)muridarum!rMOMP!adjuvanted!with!
Borrelia)burgdorferi!Outer!surface!protein! (Osp)!A! induced!significant!protection! in!
mice!against!C.!muridarum!genital!infection![150].!!
Though! most! recombinant! vaccines! have! been! based! on! MOMP,! other! novel!
vaccination! strategies! have! used! the! secreted! protein,! chlamydial! protease.like!
activity!factor!(CPAF).!!rCPAF!and!IL.12!intranasally!administered!to!mice!resulted!in!
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significantly! reduced!chlamydial! shedding! following!genital!C.)muridarum! challenge!
as!well!as!protection!against!hydrosalpinx!(distally!blocked!fallopian!tube!filled!with!
serous! fluid)! [151].! In! 2011,! Finco! et) al.! (Novartis! Vaccines)! screened! 120! C.)
trachomatis) proteins! for! their! immunogenicity! to! induce! both! CD4+/IFN.γ+! and!
antibodies! [152].! Using! protein! arrays! screened! with! sera! from! C.) trachomatis.
infected!patients!to!identify!antibody.inducing!antigens,!and!stimulating!splenocytes!





Third! generation! Chlamydia! vaccines! can! include! the! use! of! DNA,! Adenovirus! and!
MVA!based! vaccines.! The!MVA! vector! has! not! been!used! as! vaccine!platforms! for!
genital! C.) trachomatis! infections! to! date,! and! neither! has! DNA! vaccination!
adjuvanted!with! electroporation.!Only! one!Adenovirus! vectored! vaccine! against!C.)
muridarum! has! been! published! to! date,! and! conferred! significant! protection! as! a!




MOMP! administered! to! the! vaginal! mucosa! of! pigs! induced! cellular! immune!









































Chapter! 3! describes! and! assesses! the! consensus! approach! versus! the! mosaic!













































































































































































DNA! restriction! digests! were! carried! out! as! per! restriction! enzyme!manufacturers!























for!45! s),! followed!by!72°C! for!10!min.!This!PCR!product!was! separated!on!a!1.5%!
agarose!gel!and!the!DNA!extracted!and!purified!from!the!gel!by!a!QIAgen!MinElute!
gel! extraction! kit.! The! purified! PCR! product! was! topoisomerised! ligated! into! the!
TOPO!pcDNA3.1!plasmid! (Invitrogen)!according! to!manufacturers! instructions!prior!

















SW102! E.coli! were! grown! at! 32°C! before! inducing! the! lambda! red! proteins! by!
incubating!at!42°C!for!15!min.!SW102!bacteria!contain!a!defective!phage!expressing!
lambda! red! genes! which! mediate! homologous! recombination! between! DNA!
stretches! as! short! as! 50! bp.! ! These! lambda! red! genes! are! under! temperature!
sensitive!control,!remaining!turned!off!at!32°C!but!induced!at!42°C.!!!!
10!ng!of!the!purified!antigen!sequence!PCR!product!with!the!nucleotide!overhangs!
was! added! to! a! 25! μL! aliquot! of! the! freshly! induced! competent! SW102s! and!
transferred!to!pre.cooled!0.2!cm!cuvettes.!The!DNA!and!cells!were!electroporated!at!
2.50! kV! and! the! bacteria! recovered! in! 5!ml! LB! for! 4! hr! at! 32°C! at! 200! rpm.! This!
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extended!recovery!allowed!the!loss!of!sacB!DNA!and!proteins!from!the!cells!within!





overnight! at! 32°C.! ! DNA!was! extracted! using! the!QIAgen! spin!miniprep! kit! before!
diagnostic! restriction!digest.! 8!μL!of! purified!DNA!with!1!μL!NEB! restriction!buffer!
(10x)! and!1!μL!BamH1! reaction!was! incubated!at! 37°C! for! 1!hr!before! loading! the!








































digest.! The! shuttle! vector! was! also! digested! with! Kpn1.HF! and! Not1.HF.! DNA!
fragments!were!separated!on!a!1.5%!agarose!gel!and!gel!extracted!using!a!QIAgen!
MinElute!gel!extraction!kit.!DNA!from!the!MVA.GFP.TD!backbone!was!ligated!to!the!
MOMP! insert! DNA! overnight! at! 15°C! and! successful! ligation!was! confirmed! by! an!
analytical! restriction! digest.! This! was! further! confirmed! by! sequencing! (MWG!





A! vial! (50! μL)! of! either! chemically! competent! TOP10! Escherichia) coli! (E.) coli)!






















time! storage! at! .80°C.! The! remaining!bacterial! overnight!was!purified!by! endofree!
Qiagen! plasmid!maxiprep! kits! and! the! DNA! concentration!measured! by!Nanodrop!




The) C.) trachomatis! serovar! D! plasmid! encoded! protein! 3! (Pgp3)! sequence! cloned!
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into! a! glutathione! S.transferase! (GST).fusion! protein! expression! vector! was! kindly!
provided!by!Dr.!Guangming!Zhong!(University!of!Texas!Health!Science!Center!at!San!
Antonio).! To! initiate!Pgp3!protein!production,!bacterial! stocks!were!picked! into! LB!
broth! plus! carbenicillin.! This! was! shaken! at! 37°C! at! 300! rpm! until! the! OD600!
measured!0.8!on!Nanodrop!before!IPTG!was!added!(200!μM)!to!induce!expression.!
The! culture! was! then! reduced! to! 30°C! with! 200! rpm! shaking! for! 3! hr.! Cells! were!
harvested!by!centrifugation!(6000g,!15!min)!and!the!bacterial!pellet!resuspended!in!
Tris!buffer.!The!bacteria!were!lysed!by!five!freeze!thaw!cycles!before!centrifugation!













After! separation!of! the!proteins!on! the!gel!with!discontinuous! reducing!SDS.PAGE,!
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they! were! transferred! to! nitrocellulose! membrane! by! semi.dry! electrophoresis.!
Transfer! was! achieved! by! applying! a! 20! V! constant! voltage! for! 20! min.!




at! room!temperature!with! the!primary!antibody!diluted! in! the!blocking!buffer!at!a!






To! determine! the! genotype! of! IFN.γ! KO! mice! (bred! in.house),! ear! punches! were!


































droplet! reading! for! ddPCR! were! carried! out! according! to! the! manufacturer’s!









hr!prior! to!transfection.!4!μg!of! recombined!HuAd5!vector!was!diluted! into!100!μL!
DMEM!without!FCS!or!antibiotics!and!40!μL!Polyfect!was!added!before!incubating!at!
room! temperature! for! 10!min.! To! this! DNA! complex,! 1!ml! complete!medium!was!
added!and! transferred! to! the! confluent!293TREx! cells.! 293! cells! are!permissive! for!
the!production!and!amplification!of!replication.incompetent!adenovirus,!as!the!cells!
provide!the!E1!and!E3!gene!products!in)trans.!Cells!were!incubated!at!37°C,!5%!CO2!
in! a! humidified! incubator.! Cells! were! monitored! daily! for! cytopathic! effect! (CPE),!
with! fresh!media! added! every! 2.3! days.!When! complete!CPE!was! visible,! the! cells!
were! harvested! by! cell! scraping,! and! centrifuged! at! 500g! at! 4°C! for! 10! min.!!
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Adenovirus! was! released! from! the! cells! by! four! freeze.thaw! cycles! in! a! dry!
ice/methanol!bath!and!centrifuged!at!500g!at!4°C!for!15!min!to!obtain!a!cleared!viral!
supernatant.!After!rounds!of!large.scale!amplification!of!the!adenovirus,!the!cleared!




18G! needle! through! the! side! of! the! tube.! The! extracted! virus! was!mixed! with! 2x!
adenovirus!storage!buffer!and!frozen!as!aliquots!at!.80°C.!!!
Virus! yield! was! determined! by! single! cell! immunostaining.! Purified! recombinant!





34065)!was! added! to! the! fixed!antibody! stained! cells! and! incubated! for! 10!min!at!








All! procedures! were! carried! out! in! accordance! with! the! terms! of! the! UK! Animals!
(Scientific!Procedures)!Act!Project!Licence!(PPL!70/7457)!and!were!approved!by!the!
Ethical! Review! Board! of! Imperial! College.! All! mice! were! housed! in! the! Central!
Biomedical!Services!(CBS)!facility!at!St!Mary’s!Hospital!under!Specific!Pathogen!Free!
(SPF)! conditions.! Female! BALB/c! (H.2d)! (Harlan,! UK)! and! B6C3F1! (Charles! River,!
Germany)! were! 6.8! weeks! old! at! commencing! of! experiments.! IFN.γ! KO! mice!
(C57BL/6!background)!were!kindly!provided!by!Dr!John!Tregoning!(Imperial!College!
London).!
















Intravaginal! (i.vag.)! vaccinations!were!administered!under!anaesthesia! in!a!volume!
of!20!μL!by!positive.displacement!pipette!(Gilson).!
Electroporation! was! with! 5!mm! electrodes! at! the! injection! site! immediately! after!





DNA! vaccines! were! prepared! in! sterile,! endotoxin! free! PBS,! and! dosed! on!
concentrations! determined! by! Nanodrop! at! absorbance! 260! nm.! Viral! vectored!
vaccines!were!prepared! in!sterile,!endotoxin! free!PBS.!Viral!vectors!were!dosed!on!
PFU! (plaque! forming! units)! to! ensure! equivalent! doses! between! subsequent!
preparations.! Protein! vaccines! were! prepared! in! sterile,! endotoxin! free! PBS,! and!
mixed!1:1!with!the!adjuvant!MF59!(Novartis).!MOMP!concentration!was!determined!












PBS/BSA! for! at! least! 1! hr! at! 37°C.! Plates!were!washed! again! as! before.! Sera!were!









This!procedure!was! carried!out! for! antigen.specific! IgA! responses,! except!with! the!
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alteration! of! using! a!mouse! IgA! standard! (Sigma! Aldrich)! and! detecting!with! anti.
mouse!IgA.HRP.!!
This!procedure!was!carried!out!for!antigen.specific!IgG1!and!IgG2a!responses,!except!
with! the! alteration! of! using! a! respective! mouse! IgG1! or! IgG2a! standard! (Sigma!













incubating! with! anti.mouse! IgG.HRP.! Samples! were! developed! with! TMB! as!
described!above.!The!avidity!index!was!calculated!as!the!percentage!of!urea!treated!
OD450!nm/!PBS.T!OD450!nm.!Antisera!with!index!values!exceeding!50%!were!ascribed!as!





MOMP!derived! peptides! used! in! cellular! assays!were! commercially! synthesised! by!
JPT! Peptide! Technologies! GmbH.! Peptide! lengths! were! 15mers,! with! 96! peptides!





Mice! were! sacrificed! by! cervical! dislocation! and! spleens! removed! by! dissection.!
Spleens!were!macerated! in! complete!RPMI!medium! through! a! 70!μm! cell! strainer!
and!centrifuged!(500g,!5!min).!Supernatants!were!discarded!and!pellets!resuspended!
in!4!ml!ACK! lysis!buffer! for!5!min!before! the!addition!of!5!ml!PBS/2.5%!FCS.! !Cells!
were!recentrifuged!(500g,!5!min)!and!resuspended!in!5!ml!PBS/2.5%!FCS.!!
Splenocytes! were! counted! using! a! Scepter! 2.0! handheld! automated! cell! counter!






IFN.γ! ELISpots! were! carried! out! to! quantify! the! number! of! IFN.γ! secreting!
splenocytes! under! antigen! specific! peptide! stimulation.! Pre.coated! mouse! IFN.γ!
ELISpot! plates! by! MABtech! were! used! as! per! manufacturers! instructions.! Briefly,!
plates!were!blocked!with!complete!media!for!at!least!30!min!at!room!temperature.!





6A2.biotin)! at! 1! μg/ml! was! added! at! 100! μL/well! for! 2! hr! at! room! temperature.!
Plates!were!washed!a!further!five!times!with!PBS.!Streptavidin.ALP!(1:1000)! in!PBS!
was!added!at!100!μL/well!and!incubated!for!1!hr!at!room!temperature.!Plates!were!
washed! a! further! five! times!with! PBS! before! the! substrate! solution! BCIP/NBT.plus!
was!added!at!100!μL/well.!The!plates!were!developed!until!distinct!spots!emerged.!










in!anti.mouse!CD16/CD32! (Fc!block)! for!15!min.!Cells!were!washed! in! FACS!buffer!
and! surfaced! stained!with! anti.CD3e!PE,! anti.CD4!APC!and!anti.CD8a!eFluor605NC!
for! 30!min.! After! permeabilisation! using! Cytofix/Cytoperm! cells! were!washed! and!
stained! intracellularly! with! anti.IFN.γ! PeCy7,! anti.TNF.α! FITC! and! anti.IL.2! perCP!
Cy5.5! for! 30! min.! Samples! were! washed! and! resuspended! in! 1.5%! PBS! Formalin!

















extraction! buffer! (Chapter! 2.1.2)! was! pipetted! onto! each! murine! eye! and!
subsequently! absorbed! with! 2! mm! x! 5! mm! PVA! swabs.! The! swabs! were! then!
incubated!with!an!additional!50!μL!of!ocular!extraction!buffer!at!room!temperature!







C.) trachomatis! E.Bour! was! supplied! by! the! American! Tissue! Culture! C! (ATCC).! C.)
trachomatis! D/UW3.cx! was! kindly! provided! by! Dr.! R.! Carabeo,! Imperial! College!







agitated! until! thawed.! The! EBs! were! diluted! to! an! appropriate! concentration! in!
sterile! SPG! buffer! such! as! there! is! infection! at! a! multiplicity! of! infection! of! 1.10!
EBs/host! cell.! ! The! culture! medium! was! removed! from! the! McCoy! cells! and! an!
appropriate! amount! of! diluted! EBs! added! to! each!well! or! flask.! The! tissue! culture!
plates! were! then! centrifuged! at! 900g! for! 1! hr! at! room! temperature.! Complete!





The! culture! medium! from! C.) trachomatis.infected! McCoy! monolayer! cells! was!
decanted!and!replaced!with!5!ml!SPG.! !The! infected!cells!were!dislodged! from!the!
flask! with! disposable! sterile! cell! scrapers! and! transferred! to! chilled! screw.cap!
microcentrifuge!tubes!containing!three!3!mm!glass!beads.!The!cell!mixture!was!then!
vortexed! for! 1! min! to! allow! the! beads! to! tear! open! the! infected! cells.! The! cell!
suspension!was!centrifuged!at!100g!for!5!min!at!0°C,!and!the!supernatant!carefully!
aspirated! and! kept.! The! supernatant! was! subsequently! analysed! by! dynamic! light!






McCoys! were! seeded! in! 96! well! tissue! culture! plates! with! complete!medium! and!
incubated!for!24!hr!at!37°C,!5%!CO2!until!confluent.!The!EB!aliquot!to!be!titered!was!
quickly!thawed!and!kept!on!ice!before!the!EBs!were!diluted!over!ten.fold!ranges!(10.
1! to! 10.6)! in! SPG!buffer! to! a! volume!of! 350!μL.! The! culture!medium!was! removed!
from!the!monolayers!and!100!μL!of!each!dilution!added! to! three!wells.! The! tissue!
culture! plates! were! then! centrifuged! at! 900g! for! 1! hr! at! room! temperature.!
Complete! Chlamydia! media! is! then! added! to! the! infected! cells! and! the! cells!
incubated!at!37°C,!5%!CO2!for!24!hr.!After! incubation!the!medium!was!then!gently!
aspirated! and! 100! μL! of! 100%!methanol! added! to! each! well! for! 10! min! at! room!
temperature.!After! the!methanol.fixation,! the! cells!were!washed!3! times!with!PBS!
before! primary! antibody! staining! with! rabbit! anti.MOMP! serum! (1:150! dilution).!!
This!primary!antibody!was!incubated!at!room!temperature!for!1!hr!before!washing!
the! cells! three! times! with! PBS.! Goat! anti.Rabbit! H+L–Alexa594! was! added! as! the!
secondary! antibody! to! the! cells! for! 1! hr! at! room! temperature! (1:1000! dilution)!
before!another!three!washes!with!PBS.!Fixed!and!stained!cells!were!stored!in!PBS!at!
4°C! until! fluorescent! microscopy.! Using! a! hand.held! counter,! all! fluorescent!














sample! preparation! prior! to! infection.! The! rayon! swabs! following! murine! vaginal!
sampling!were! stored! in! 500! μL! SPG! buffer,! prior! to!mechanical! disruption! of! the!
swab!by!vortexing!glass!beads.!The!SPG!buffer!was!then!aliquoted!to!120!μL!volumes!





A! neutralisation! assay! was! carried! out! to! assess! the! ability! of! antibodies! raised!
following! immunisations! to! inhibit! the! infection! of! C.) trachomatis! EBs! into! cells!






well! tissue! culture! plates! and! titered! as! in! 2.2.4.4.! Mean! neutralisations! were!
calculated! as! the! average! reduction! in! inclusion! forming! units! for! each! regimen!





The! MOMP! consensus! antigen! was! created! using! Consensus! Maker! v2.0.1!
(http://www.hiv.lanl.gov/content/sequence/CONSENSUS/consensus.html).! The!
‘Advanced’! tool! was! used! to! make! a! consensus! of! blocks! of! sequences! in! an!
alignment!using!the!following!parameters.! !The!minimum!number!of!sequences!for!
consensus!was! set! to! 3,! with! no! consensus! of! consensuses.! The! unanimous! value!
was!set!to!1.00,!with!a!majority!value!of!0.50,!using!the!most!common!character!at!
each!alignment!point.!Nucleotides!were!set!to!AGCTU.,!and!the!character!set!for!the!
making! of! the! consensus! included! ARNDCEQGHILKMFPSTYWV.! amino! acids.! The!
majority!value!was!incrementally!increased!to!find!the!most!stringent!consensus.!




The! cocktail! size!was! set! to! 1,!with! epitope! length! of! 9! (to! allow! the! software! to!




the! consensus! or! the! mosaic! antigen! was! calculated! with! the! Epitope! Coverage!
Assessment! Tool! EPICOVER! ! (http://www.hiv.lanl.gov/content/sequence/MOSAIC/!
epicover.html).! The! settings! included! a! nominal! epitope! length! of! 9! ! (to! allow! the!
software!to!cover!Class!I!and!II),!with!a!maximum!amino!acid!mismatch!of!2!in!order!
to!score,!and!a!minimum!of!3!occurrences!of!a!potential!epitope! in! the!test!set! to!
consider!for!coverage.!Precision!was!set!to!4!decimal!places,!and!the!subsets!were!
defined!on!the!first!character!in!the!sequence!names!(the!serovar!designation).!!!
A! guide! tree! of! the! ompA! serovar! E! variants! and! the! amino! acid! properties! were!
analysed!within! the!Align! section! of!UniProt! ! (http://www.uniprot.org/).! Following!
the! alignment! of! the!ompA) serovar! E! variant! sequences! in! FASTA! format,! a! guide!
tree! is! constructed! via! a! UPGMA! cluster! analysis! of! the! pairwise! alignments!








For! non.parametric! data! the! Kruskal.Wallis! test! with! Dunn’s! multiple! comparison!
post.test! was! used! to! compare! more! than! two! groups,! or! the! two.tailed! Mann.
Whitney! test! to!compare! two!groups.!For!parametric!data,!a!one.way!ANOVA!was!
used!for!multiple!comparisons,!with!Bonferroni’s!multiple!comparison!post.test! for!
comparison!of!specific!groups.!!P!≤!0.05!was!considered!significant!(*!p!≤!0.05,!**!p!≤!
0.005,! ***! p! ≤! 0.0005! and! ****! p! ≤! 0.0001).! The! log.rank! (Mantel.Cox)! test! and!


































Chlamydia! vaccine! research! has! mainly! focused! on! the! Major! Outer! Membrane!
Protein! (MOMP)! as! the! primary! vaccine! antigen! and! some! results! have! been!
encouraging! while! others! rather! disappointing.! In! 1997,! Pal! et! al.! found! that! a!
chlamydial! outer! membrane! complex! (COMC)! preparation! of! C.) muridarum) could!
significantly!protect!mice!against!a!genital!challenge![147]!and!then!some!years!later!
the! same! team! demonstrated! that! a! purified! and! refolded! preparation! of! the! C.)
muridarum! MOMP! conferred! a! significant! level! of! protection! against! a! genital!
challenge![148].!Furthermore,!the!immunisation!of!mice!with!purified!C.)muridarum!
MOMP! could! induce! neutralising! antibodies! [160].! Igietseme! et! al.! prepared! a!
MOMP.ISCOM! vaccine! with!MOMP! extracted! from! C.) trachomatis! serovar! D,! and!
immunised!mice!cleared!a!vaginal!infection!with!one!week![161].!These!studies!show!
that!some!MOMP!preparations!can!induce!more!protection!than!others.!This!is!most!
likely! due! to! the! difference! in! extraction! methods,! which! can! influence! the!
conformation!and/or!presentation!of!epitopes!that!may!be!necessary!for!protection.!
The! immunogenic! refolded,! purified! MOMP! preparations! however! are! very!




technology,! which! costs! less! and! is! technically! more! efficient,! and!MOMP! is! now!
generally! made! by! this! recombinant! technology.! However,! the! expression! of! full.
length! rMOMP! in! E.) coli! is! often! toxic! and! it! is! difficult! to! produce! rMOMP! with!
conformationally! relevant! epitopes! [162].! rMOMP! has! however! been! used! in! an!
attempt! to!elicit!C.) trachomatis! protection.!The! transcutaneous! immunisation!with!
rMOMP!adjuvanted!with!cholera!toxin!and!CpG!resulted!in!the!enhanced!clearance!
of! C.) muridarum! following! intravaginal! challenge! in! mice! [149].! Furthermore! in! a!
comparison! between! C.) muridarum! recombinant! MOMP! and! native! MOMP,! the!




trachomatis! proteins! for! their! ability! to! induce! both! CD4+/IFN.γ+! T! cell! responses!
and!antigen.specific!antibodies![152].!Using!protein!arrays!screened!with!sera!from!C.)
trachomatis.infected! patients! to! identify! antibody.inducing! antigens,! and! by!
stimulating! splenocytes! from!C.) trachomatis.infected!mice! to! identify! CD4+/IFN.γ+!
inducing! antigens,! they! discovered! only! five! antigens! eliciting! both! types! of!
responses.!!MOMP!was!one!of!these!five!antigens.!!
As! a! collection,! all! these! studies! strengthen! the! argument! to! use! MOMP! as! the!
antigen! throughout! our! vaccine! studies.! Moreover,! as! some! of! these! vaccine!
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platforms! have! yet! to! be! used! in! chlamydia! vaccine! research,! let! alone! in!
heterologous! prime.boost! regimens,! it! is! appropriate! to! use! an! established!
chlamydial!antigen!in!order!to!be!able!to!compare!against!previous!research.!!
MOMP,! encoded! by! the! ompA! gene,! is! one! of! the! predominant! proteins! at! the!
surface!of!both!EB!and!RB!forms,!making!up!60%!of!total!outer!membrane!protein!
[146].!MOMP!has!a!molecular!mass!of!~40!kDa,!and!has!been!published!as!having!
functions! as! a! structural! protein! [164],! a! general! porin! [165]! [166]! [167],! and! a!
chlamydial!cytoadhesin![168]![169].!!!The!most!accepted!function!of!MOMP!is!that!of!
a!porin,!serving!as!a!general!diffusion!porin!being!strongly!size.selective!but!not!ion.
selective! [170].! Despite! years! of! research,! the! real! structure! of! MOMP! is! still!
unknown.! Using! secondary! structure! prediction! methods,! variable! domains! (VDs)!
were! located! on! the! outer! loops! and! exposed! on! the! surface,! consistent! with!
immunogenicity!and!infectivity!data!(Figure!3.1)![171]![172].!!
The! breakthrough! in! cloning! and! sequencing! of! the! ompA! gene! of! C.) trachomatis!
revealed!extensive!DNA!sequence!variation!and!correlated!with!observed!molecular!
weight!variation![173]![174]![175].!In!this!respect!C.)trachomatis!was!different!to!C.)
pneumoniae! where! there! is! comparatively! less! variability! in! MOMP! [176].! The!
variation! of!C.) trachomatis!MOMP! is!mostly! isolated! to! four! variable! segments! or!
domains!(termed!VS!or!VD!1!to!VD4),!which!include!subspecies.!and!serovar.specific!
antigenic! determinants! [171].! The! typing! of! C.) trachomatis! is! based! on! the!
serological! differentiation! of! antigenic! epitopes! on! MOMP! into! 19! human! C.)
trachomatis!serovars!(A!to!K,!Ba,!Da,!Ia,!Ja,!L1!to!L3,!and!L2a).!Based!on!amino!acid!
similarities,! these! serovars!are!grouped! into! the! following! serogroups!or! classes:!B!
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class! ! (B,! Ba,!D,!Da,! E,! L1,! L2! and! L2a),! C! class! (A,! C,!H,! I,! Ia,! J,! Ja,! K,! and! L3),! and!
intermediate! class! (F! and! G)! [177]! [178]! [179].! Generally,! type! specific! antibodies!
show! specificities! for! one! of! these! serovars! only;! sub.species! specific! antibodies!
show! specificities! for! the! class! to! a! varying! extent;! and! species! specific! antibodies!
show!specificities!for!the!whole!C.)trachomatis!species![180]![181].!!!!
!
In! our! vaccine! design! we! sought! to! use! a! MOMP! antigen! that! encompassed! the!
broadest! coverage! of! these! different! serovar! groups! and! classes! and! thus! have! a!
strong! translational! potential.! We! investigated! both! a! consensus! and! a! mosaic!
antigen!approach!to!encompass!the!amino!acid!variability!of!MOMP.!Mosaic!vaccine!
antigens! are! composite! proteins,! optimised! to! include! the! maximum! number! of!
potential! T! cell! epitopes! from! a! set! of! samples.! The! mosaics! are! generated! from!
natural!sequences!and!resemble!natural!proteins!but!systematically!include!common!
(and! exclude! rare)! potential! epitopes.! The! mosaic! approach! has! been! extensively!
analysed! for!HIV!proteins,!but! can!be!applied! to!any!variable!protein!and! to!other!
pathogens![182].!Consensus.based!vaccines!rely!on!a!centralised!antigen!designed!to!
reduce!sequence!diversity!by!using!the!most!common!amino!acid!at!each!position!of!
the! protein.! Consensus! vaccines! are! designed! to! reduce! the! genetic! differences!

























(A)! Backbone! and! (B)! predicted! topology! of! C.) trachomatis) serovar! C! MOMP! monomer.! Figures!
adapted!from!Feher!et)al.,!2013![184].!The!backbone! is!a!superposition!of!10! low!energy!monomer!
structures!,!with!ribbon!colours!illustrating!the!relative!deviations!of!the!heavy!atoms!to!the!average!






The! aim! of! this! chapter! is! to! computationally! assess! whether! the! amino! acid!
variability! within! the! Chlamydial! antigen! MOMP! can! be! encompassed! within! a!
consensus! or! a! mosaic! based! vaccine.! In! this! chapter! consensus! and! mosaic!
approaches!will!be!bioinformatically!analysed!to!assess!which!approach!provides!the!
greater!coverage!of!worldwide!circulating!MOMP!sequences.!Based!on!this!analysis!
the! optimal! antigen!will! be! expressed! from! four! differing! vaccine! platforms;! DNA,!




• To! computationally! assess! whether! the! amino! acid! variability! within! the!
Chlamydial!antigen!MOMP!can!be!encompassed!within!a!single!antigen.!
Objective!
• Consensus! and! mosaic! approaches! will! be! bioinformatically! analysed! to!








Though! MOMP.based! vaccines! have! induced! strong,! near! protective! immunity! in!
animal! models,! there! is! significant! diversity! in! the! amino! acid! sequence! of! the!
protein!(encoded!by!ompA),!and!the!serovar!typing!of!C.)trachomatis!is!based!on!this!
MOMP! variability.! To! date! there! isn’t! a! known! worldwide! prevalence! of! specific!
urogenital!C.)trachomatis!serovars,!therefore!a!literature!review!was!undertaken!to!
investigate! this.! Pubmed! searches! for! the! terms! “chlamydia! trachomatis! serovar!
prevalence”!and!“ompa!trachomatis!prevalence”!were!undertaken!in!October!2011.!
Research!articles!were!only! included! if! they!stated! the!serotype!and! the!serotypes!
percentage! prevalence! or! relative! prevalence! to! other! serovars.! Unless! otherwise!
stated,!only!serovar!prevalence’s!from!genital!C.)trachomatis!samples!were!included,!
albeit! from! either!male! or! female! subjects.! ! From! this! PubMed! search! in!October!
2011,! only! 13! publications! described! the! country! or! regional! serovar.specific!
prevalence.!A!subsequent!PubMed!search!in!November!2014!provided!an!additional!
5! publications! describing! country/regional! serovar.specific! prevalence’s.! Serovar! E!
clearly!revealed!itself!to!be!the!most!prevalent!in!the!majority!of!cases,!accounting!
for!49%!of!cases!in!Australia!(2011),!46%!in!Buenos!Aires,!Argentina!(2010),!and!41%!






3.2.2 Encompassing!MOMP! variability! in! a! consensus! and!mosaic! vaccine!
antigen!
However,!there!is!amino!acid!variability!in!the!protein!MOMP!between,!and!within,!
serovars.! To! account! for! the! amino! acid! variability! in! MOMP! within! serovar! E,! a!
consensus! approach! was! undertaken! using! over! 1500! serovar! E! ompA! sequences!
obtained!worldwide!and!generously!provided!by!Prof.! Joao!Gomes! (NIH,!Portugal).!
These!sequences!were!surveyed!from!a!total!of!5026!C.)trachomatis!strains!isolated!
in! 33! distinct! geographic! regions! from! five! continents! [189].! These! samples! were!
sourced! from!both!hetero! and!homosexual! patients! from!general! practices,! family!
planning! centres,! obstetrics! and! STD! clinics.! They! found! 49! ompA! variants! within!
their!serovar!E!samples,!and!these!sequences!were!used!for!an!in)silico!generation!of!
a! consensus! sequence.! The! Los! Alamos! Consensus! Online! Program!
(http://www.hiv.lanl.gov/content/sequence/!CONSENSUS/consensus.html)!was!used!
on!the!49!variant!sequences,!which!aligns!the!49!sequence!reads!and!calculates!the!
majority! amino! acid! at! each! position! before! providing! a! consensus! identity.! ! The!
consensus! sequence! calculated! had! a! 61%! identity,! and! matched! the! circulating!
strain!E.Bour.!However,!from!an!amino!acid!guide!tree!of!the!49!variants,!there!was!
significant!clustering!of!CalE!samples.!After!blocking!for! these!11!CalE!variants,! the!
consensus!still! remained!as! the!strain!E.Bour!but! its!coverage! identity!dramatically!











Country!(Year)! D! E! F! G! H! I! J! K!
Amsterdam!(Holland)!(1995)![190]! ! ! ! ! ! ! ! !
Australia!(2008)![191]! ! 49%! 22%! 6%! ! ! ! 6%!
Buenos!Aires!(Argentina)!(2010)![192]! 19%! 46%! 15%! ! ! ! ! !
China!(2007)![193]! 11%! 27%! 23%! 12%! ! ! ! !
Greece!(2010)![194]! ! ! ! ! ! ! ! !
Hafner!(2008)![195]! ! ! ! ! ! ! ! !
Holland!(2000)![196]! 12%! 44%! 22%! ! ! ! ! !
Hungary!(2009)![197]! 34%! 22%! 19%! 9%! ! ! ! !
Italy!(2009)![198]! 20%! 25%! 16%! 19%! ! ! ! !
Japan!&!Thailand!(1990s)!![199]! 32%! 18%! 17%! ! ! ! ! !
Papua!New!Guinea!(2007)![200]! 30%! 21%! 25%! ! 20%! ! ! !
Russia!(2009)![201]! 10%! 34%! ! 26%! ! ! 8%! !
Seattle!(USA)!(1988.1996)![202]! 13%! 32%! 18%! ! ! ! ! !
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EPICOVER!calculates!the!proportion!of!all!epitope.length!peptides!in!the!test!set!that!
are! matched! by! some! peptide! or! peptides! in! each! designed! antigen.! EPICOVER!
analyses! at! a! nominal! epitope! length! of! 9,! for!which! the! program! is! optimised! to!
analyse! both! Class! I! and! II! epitopes;! allows! up! to! 2! maximum! amino! acid!
mismatches;! and! requires! a! minimum! of! 3! occurrences! of! the! epitope! from! the!
epitope!test!set!to!consider! it!as!part!of!the!coverage.!The!consensus!has!an!exact!




There! are! advantages! to! the! consensus! sequence! of!MOMP!matching! that! from!a!
wild.type! circulating! strain! (E.Bour).! Firstly! it! ensures! that! the!MOMP!will! have! a!
natural,! functioning! protein! structure,! and! secondly! it! allows! for! homologous!
challenges!using!actual!C.) trachomatis! strain!E.Bour!elementary!bodies.! To! further!




that! may! influence! the! protein! folding,! the! transmembrane! anchoring! during!
production!or!the!functionality!of!the!mature!protein.!!
As! a! comparison! to! the! consensus! approach,! a! mosaic! vaccine! strategy! was!
investigated.!Mosaic!vaccines!use!natural!sequences!to!generate!a!small!number!of!
mosaic! sequences! that! include! the! maximal! diversity! of! potential! T! cell! epitopes!
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from!circulating!sequences.!This!method!was!first!applied!to!HIV!antigens!due!to!the!
large! genetic! diversity! in! the! virus,! but! has! not! yet! been! applied! to! any! C.)
trachomatis)protein.!A!mosaic!protein! is!an!artificial! recombinant!protein!designed!
from!a!set!of!reference!protein!sequences!so!that!every!constituent!peptide!is!found!
in! some! place! in! the! set! of! input! proteins.! A! mosaic! vaccine! was! designed!
(http://www.hiv.lanl.gov/content/sequence/MOSAIC/makeVaccine.html)! from! the!
MOMP! variant! sequences! of! both! D! and! E! serovars,! and! the! epitope! coverage!
assessed!by!EPICOVER!(Figure!3.3B).!The!mosaic!provided!exact!epitope!coverage!of!
76.31%! against! serovar! E! variants,! 64.82%! against! serovar! D! variants,! and! 70.81%!
against! all! four! serovars.! The! mosaic! vaccine’s! overall! epitope! coverage! is!
comparable!to!that!of! the!consensus!vaccine,!but!the! lower!coverage!for! the!most!
prevalent!serovar!E!and!particularly!the! lack!of!a!native!MOMP!structure!given!the!
expression! difficulties! experienced! by! researchers! in! the! past! argued! against! the!
mosaic! approach! for! this! work.! From! this! evidence! I! was! confident! to! use! the!
consensus!MOMP! sequence! as! the! antigen! in! the! vaccines! developed! throughout!

























A)! Consensus! and! B)! Mosaic!MOMP! antigens.! Mean! coverage! of! either! the! consensus! or! mosaic!
MOMP! antigen! against! the! 134! variant! MOMP! sequences! (provided! by! Gomes,! NIH! Portugal),!
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The! full!methodologies! and!details! on! the! constructions! of! the!DNA,!HuAd5,!MVA!
and!recombinant!MOMP!vaccines!are!described!in!Chapters!2.2!and!2.3.!Briefly,!the!
human! codon!optimised! consensus!MOMP! sequence!was! synthesised!by!GeneArt,!
and!cloned!into!the!plasmid!pcDNA3.1!to!form!the!DNA!vaccine.!For!the!construction!
of! the! HuAd5! vaccine,! the! same! synthesised! consensus! MOMP! sequence! was!
homologously! recombined! into! the! E1! and! E3! deleted! HuAd5! genome! plasmid,!
pAL1112.! Successfully! recombined! clones! were! transfected! into! 293TREx! cells! to!
propagate!HuAd5!virus.!The!synthesised!consensus!MOMP!was!successfully!cloned!
into!the!MVA.GFP.TD!shuttle!plasmid!before!being!sent!to!The!University!of!Oxford!
Viral!Vector!Core! Facility!where! the!plasmids!were! transfected! and! the!MVA!virus!
propagated! and! purified.! For! the! recombinant! MOMP! protein,! an! E.) coli! codon!
optimised!consensus!MOMP!sequence!was!synthesised!by!GeneArt!and!cloned!into!
the! bacterial! expression! plasmid! pET101,! but! this! protein! expressed! at! too! low! a!








vaccines! was! confirmed! by! polyclonal! anti.MOMP! Western! blots! (Figure! 3.4).!
MOMP.DNA!was!transfected!into!293TREx!cells,!and!the!cell!lysate!and!supernatant!
analysed!24!hr!post!transfection!by!anti.MOMP!western!blot.!MOMP!was!expressed!
at! the! correct! molecular! weight! (40! kDA)! in! the! cell! lysate! following!MOMP.DNA!








system.! Consensus! MOMP! recombinant! protein! could! not! be! expressed! to! high!
enough! yields! in! the!E.) coli! expression! system! for! use! as! a! vaccine.! Induction! and!
expression! of! the! consensus!MOMP! recombinant! protein!was! compared! against! a!
serovar! D! MOMP! recombinant! protein! (kindly! provided! by! Dr.! Frank! Follmann,!





MOMP!was! used! throughout! this! thesis! as! the! recombinant! protein! vaccine.! It! is!
unclear! how! the! eight! amino! acid! differences! between! the! consensus!MOMP! and!




































MOMP!production! from!E.coli!was! confirmed!by!Coomassie.!Coomassie!gel! reveals!poor! consensus!
MOMP!yield!following!expression!in!E.coli!in!comparison!to!the!MOMP!serovar!D!antigen.!Lanes!1!&!4!
are!non.purified!soluble!proteins!expressed!following!induction,!lanes!2!&!5!are!flow!through!proteins!
(unbound)! following! HIS.purification! of! the! soluble! protein! fraction,! and! lanes! 3! &! 6! are! eluted!
proteins!(bound)!following!HIS.purification!of!the!soluble!protein!fraction.!!!!!
40 kDa 







in) vivo! dose! titration!was! performed! for! each! one! in! turn.! The! immunisation! and!
sampling!schedule! for! the! in)vivo!dose! titrations!are! represented! in!Figure!3.5!and!
for! each! vaccine! type! (DNA,! HuAd5,! and! MVA)! the! MOMP.specific! serum! IgG!
concentration!and!the!MOMP.specific!T!cell!IFN.γ!production!was!measured!(Figure!
3.6).!
All! DNA! immunisations! were! delivered! intramuscularly! with! electroporation! as!
described! in! Chapter! 2.4.2.! A! dose! of! 0.5! –! 50! μg!was! evaluated! for! induction! of!
MOMP.specific! IgG! (Figure! 3.6A).! There! were! significantly! higher! serum! MOMP.
specific!IgG!concentrations!following!vaccination!with!50!μg!DNA!doses!compared!to!
0.5! μg! doses! or! unvaccinated! naïve! controls! (*p) ≤! 0.05,! one! way! ANOVA! with!
Bonferroni’s! multiple! comparison! post.test),! with! a! mean! concentration! of! 13.8!
μg/ml! MOMP.specific! IgG! following! four! 50! μg! DNA! immunisations! with!




with! Dunn’s! multiple! comparison! test).! Four! 50! μg! DNA! immunisations! with!
electroporation!measured!a!median!of!335!IFN.γ!SFU/106!splenocytes,!with!the!5!μg!













For! the! HuAd5! construct! a! dose! titration! of! 106! –! 108! PFU! was! performed.! The!
intramuscular! HuAd5! immunisation! was! the! boost! to! a! DNA! prime,! with! the!
vaccination!and!sampling!schedule!presented!in!Figure!3.5B.!The!HuAd5!was!a!boost!
to!a!DNA!prime!instead!of!just!a!HuAd5!prime!alone!to!allow!dose!effect!differences!
to! be! distinguishable,! and! a! HuAd5! prime.HuAd5! boost! was! avoided! in! order! to!
circumvent!any!potential!vector! immunity! issues.!A!dose!titration!of!106!–!108!PFU!
was! evaluated! for! the! induction! of! MOMP.specific! IgG! (Figure! 3.6B)! There! were!
significantly! higher! serum!MOMP.specific! IgG! concentrations! following! vaccination!
with!107!PFU!or!108!PFU!HuAd5!compared!to!unvaccinated!naïve!controls!(*p)≤!0.05,!
one! way! ANOVA! with! Bonferroni’s! multiple! comparison! post.test),! with! a! mean!
concentration! of! 2.7! μg/ml!MOMP.specific! IgG! for! 107!PFU! and! 3.5! μg/ml!MOMP.
specific! IgG!for!108!PFU!HuAd5.!A!dose!titration!of!107!–!108!PFU!was!assessed!for!
the! induction! of! cellular! responses! (Figure! 3.6B).! There! were! significantly! greater!
MOMP.reactive! IFN.γ!SFU! from!splenocytes! from!mice!vaccinated!with!107!PFU!or!
108!PFU!HuAd5!compared!to!unvaccinated!naïve!controls!(*p)≤!0.05,!Kruskal.Wallis!
with! Dunn’s! multiple! comparison! test),! with!median! values! of! 246! and! 267! IFN.γ!
SFU/106! splenocytes! for! 107! and! 108! PFU!HuAd5! respectively.!We! decided! upon! a!
HuAd5!dose!of!107!PFU!for!future!immunisations!as!107!PFU!was!the!lowest!dose!to!



































































































































































mice! were! sacrificed! one! week! post! final! immunisation! and! splenocytes! were! assessed! by! IFN.γ!
ELISpot!for!MOMP.reactive!T!cells!using!15.mers!overlapping!by!11!amino!acid.!Graph!is!expressed!as!


















HuAd5! titration,! the! intramuscular! immunisation! was! the! boost! to! a! DNA! prime!
(Figure!3.5B).!A!dose! titration!of!104!–!106!PFU!was!evaluated! for! the! induction!of!
MOMP.specific! IgG! and!MOMP.reactive! IFN.γ! SFU! from! splenocytes! (Figure! 3.6C)!
None! of! the! MVA! doses! induced! significantly! greater! serum! MOMP.specific! IgG!
concentrations!than!the!unvaccinated!naïve!controls,!with!the!highest!MVA!dose!of!
106!PFU!inducing!a!mean!concentration!of!only!181!ng/ml!serum!MOMP.specific!IgG.!
In! addition,! none! of! the! MVA! doses! induced! significantly! greater! MOMP.reactive!
IFN.γ!SFU!from!splenocytes!compared!to!unvaccinated!naïve!controls.!However,!the!














antigens! that! are!highly! conserved! in! the! targeted!pathogens.!Diphtheria,! tetanus,!
and!pertussis! vaccines! confer!protection!by! inducing!neutralising!antibodies! to! the!









against!Chlamydia)pecorum! in! koalas,! co.immunising!with!MOMP!A! and!MOMP!F.!
MOMP!A,!MOMP!F!and!MOMP!G!were!able!to!induce!systemic!and!mucosal!immune!
responses! in! the! healthy,! Chlamydia.free! koalas,! but! these! animals! were! not!
challenged![204].!Another!potential!approach!to!contend!with!the!genetic!diversity!
of! C.) trachomatis! serovars! is! to! use! non.variable! Chlamydial! antigens.! The!












pneumococcal! conjugate! vaccine! studies! have! shown! substantial! evidence! of!
serotype! replacement! [208].! Since! the! introduction! of! the! heptavalent! conjugate!
pneumococcal!vaccine!(PCV7),!the!pneumococcal!serotype!distribution!as!well!as!the!
patterns! of! antibiotic! resistance! has! changed.! Serotyping! of! Streptococcus)
pneumoniae!strains!from!across!16!Massachusetts!communities!between!2001!and!
2004! revealed! non.PCV7! serotypes! increasing! from! 34%! to! 55%,! indicating! either!
serotype! replacement! or! serotype! switch! in! which! strains! express! a! new! capsular!
serotype!to!evade!host! immunity! [209].!Given!that! the!ompA!genes!of!Chlamydiae!
have! recombination! hotspots! and! regions! that! can! transpose! between! types,!
serotype! replacement! is! a! potential!worry! in! Chlamydia! vaccine! design! and!would!
have!to!be!investigated!and!followed.up!in!population!settings.!!!
The!use!of!consensus!antigens!has!had!some!success!for!particular!diseases!in!animal!
studies.!The!failure! in!protection!with!current!HBV!vaccines! in!15%!of! individuals! is!





codon!and!RNA!optimisation! for!maximum!expression.! The! consensus! vaccine!was!
able!to!induce!strong!antigen.specific!T!cell!responses!in!C57BL/6!mice,!as!well!as!a!
high! titre! antibody! response! capable! of! recognising! a! native! HBcAg! though! there!
were! no! challenge! studies! to! assess! protective! ability! [210].! A! consensus! H5N1!
influenza!hemagglutinin!(HA)!antigen!was!designed!from!circulating!2006!strains!and!
inserted! into!a!DNA!plasmid.!Mice! immunised! intramuscularly! (via!electroporation)!
with!this!consensus!H5N1!HA!antigen!elicited!neutralising!antibodies!against!various!
H5N1!viruses!across!five!clades.!Moreover,!this!vaccine!in!mice!conferred!complete!
protection! from! H5N1! virus! challenges! against! clades! 1! and! 2.2,! and! significant!
protection! against! clade! 2.1! [211].! Rhesus! macaques! were! vaccinated! with! a!
polyvalent! mixture! of! purified! HIV.1! trimerised! consensus! Env.gp140! proteins!
encompassing! clades!A,!B,!C!and!E,! and! compared!against! a! single! consensus!Env.
gp140! representing!group!M.!Both!vaccines!elicited!anti.Env.gp140! IgG!antibodies,!
and!both!vaccines!elicited!neutralising!antibodies!against!the!HIV.1!SF162p4!isolate.!
However,! these! consensus.vaccinated! monkeys! were! not! protected! against! SHIV!
SF162p4! challenge! [183].! Inovio! Pharmaceuticals,! Inc.,! recently! revealed! positive!
interim!results! from!a!phase! I! study!of!a! consensus!based!H5N1!DNA!vaccine.!The!
VGX.3400X! study,! utilising! Inovio’s! SynCon®! consensus! design! technology,!
demonstrated!vaccine.elicited!high!antigen.specific!binding!antibody!concentrations!
and! a! four.fold! rise! in! geometric!mean! titres! in! an! HAI! assay! against! six! different!
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HIV.1! vaccine! research.! When! administered! to! monkeys,! mosaic! vaccines! elicited!
stronger! responses,! covering!more! epitopes! and!with! greater! cross.reactivity! than!
single! immunogens! [212]! [213].! Furthermore,! bivalent!HIV.1!mosaic! antigens!have!
shown!protection!against!acquisition!of!infection!with!the!difficult!to!neutralise!SHIV!
SF162p3!virus!in!rhesus!macaques.!Adenovirus/poxvirus!and!adenovirus/adenovirus!
vector.based! vaccines! expressing! HIV.1! mosaic! Env,! Gag,! and! Pol! afforded! a!
significant! reduction! in! the! per.exposure! acquisition! risk! following! repetitive,!
intrarectal! SHIV.SF162P3! challenges,! with! protection! correlating! with! vaccine.




epitope!coverage!against! the!most!prevalent! circulating!C.) trachomatis! strains!and!
the! consensus! provided! a! nearer.native! MOMP! structure! in! comparison! to! the!
mosaic!antigen.!Therefore!we!decided!to!use!the!consensus!MOMP!sequence!as!the!
antigen!in!the!vaccines!developed!throughout!this!project.!
We! carried! out! an! in) vivo! titration! of! the!DNA,! HuAd5! and!MVA! vectored!MOMP!





From! the! in) vivo! titration,! there! were! no! significantly! different! antibody! or! IFN.γ!
ELISpot!induction!between!the!5!μg!and!50!μg!doses,!and!for!comparability!to!other!
DNA! vaccines!we! decided! upon! 10! μg! DNA!with! electroporation! (Dr.! Paul!McKay,!
personal! communication).! Our! optimal! dose! for! HuAd5.MOMP! immunogenicity,!
delivered! intramuscularly,!was!1! x107!PFU.! This! is! the! same!dose!as! is! used! in! the!
adenovirus.vectored!vaccine!against!Venezuelan!equine!encephalitis!virus!in!BALB/c!
mice! [216],! and! comparable! to! dosages! used! to! provide! protective! immunity! to!
botulism![217]!and!as!a!sublingual!immunisation!to!SARS![218].!Finally,!our!optimal!
dose! for!MVA.MOMP!was!1!x106!PFU!–! the!same!dose!as!used! in!pre.erythrocytic!





tends! to!misfold! and! aggregate! [221].! These!difficulties! have!been!experienced!by!
other!groups!and! in!other!expression!systems! including!Arabidopsis) thaliana! [222].!!
To! avoid! the! difficulties! in! expressing! full! length! MOMP,! Kalbina! et) al.! formed! a!
chimeric!MOMP! polypeptide,! minimizing! the! number! of! hydrophobic! amino! acids!
from! the! transmembrane! regions! to! thus! increase! the!protein’s! solubility.!We!also!
attempted! this! chimeric! approach,! but!with! low! yields.! It!was! only! the! full! length!
!111!
MOMP!with!8!amino!acid!alterations,!made!in!collaboration!with!the!Statens!Serum!
Institute! (Copenhagen,! Denmark)! that! provided!workable! yields! of!MOMP! protein!
for! immunisations! and! immunogenicity! assessments.! It! is! uncertain! exactly! how!
these!amino!acid!alterations!affected!the!MOMP!yields;!especially!as!the!amino!acid!
sequence!matched! a! natural! circulating! Chlamydial! strain.! This! maybe! due! to! the!
expression!of!MOMP!within!E.)coli,!with!post.translational!modifications!potentially!
differing! from!those! in!Chlamydia.!Even!single!amino!acid!alterations!within! the!C.)
trachomatis! MOMP! protein! can! drastically! affect! the! protein! yields! (Dr.! Frank!
Follmann,! personal! communication)! and! may! affect! the! protein! folding,! the! pore!
formation!or!the!integrity!of!the!full!length!393!amino!acid!protein.!!!!
Overall! this! chapter! sought! to! computationally! assess! whether! the! amino! acid!
variability! within! the! Chlamydial! antigen! MOMP! could! be! encompassed! within! a!
consensus!or!a!mosaic!based!vaccine.!We!bioinformatically!attempted!to!encompass!
the! variability! of! the! chlamydial! antigen! MOMP,! with! the! consensus! approach!
providing!greater!epitope!coverage!and!native!structure!than!a!mosaic!antigen.!DNA,!
HuAd5! and! MVA! based! vaccines! were! successfully! constructed! and! their! optimal!
immunisation!dose!determined!through!in!vivo!titrations.!A!recombinant!consensus!
MOMP! was! poorly! expressed! from! E.) coli,! so! a! closely! related! MOMP! serovar! D!
antigen! was! adopted.! This! toolbox! of! MOMP.based! vaccines! will! allow! us! to!





















4 MultiWcomponent! vaccines!against!Chlamydia! trachomatis!





Established!vaccines!currently! in!clinical!use!predominantly!act!by! the! induction!of!
antibodies,! yet! stimulating! strong! cellular! immunity! has! proved!harder! to! achieve.!
New!arrays!of!alternative!antigen!delivery!systems!have!the!potential!to!induce!cell.
mediated! immunity,! such! as! DNA! vaccines,! recombinant! viral! vectors,! protein.in.







preventative! measure! for! a! range! of! intracellular! diseases,! including! malaria,!
tuberculosis! and! HIV.! Human! studies! have! confirmed! the! safety! of! the! approach,!
along! with! the! ability! to! elicit! antigen.specific! CD8+! CTLs! [224],! though! the!
magnitude!of!T!cell!responses!were!not!shown!to!be!sufficient!for!protection!against!
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malaria! challenge.! Alongside! the! development! of!DNA! vaccines,! the! emergence!of!
recombinant! viral! vectors! as! vaccine! delivery! systems,! such! as! poxviruses! and!
adenoviruses!also!showed!promise!as!effective! inducers!of! immune!responses.!The!
highly! attenuated! recombinant! vaccinia! virus! MVA! revealed! to! have! excellent!
immunogenicity! [225],! but! when! used! singly! or! with! repeated! administration!
(homologous! boosting)! did! not! produce! levels! of! T! cell! responses! that! were!






good) T) cell) responses) but) not) high) levels) of) protective) antibodies.) Therefore)
combined)immunisation)including)both)of)these)two)types)of)vaccines)may)be)more)
effective)than)either)immunogen)alone”)[227].!!
Priming! the! immune! system! against! a! target! antigen! and! subsequently! boosting!
antigen.specific!immune!responses!with!a!different!distinct!immunogen!can!result!in!
the! synergistic! enhancement! of! specific! immunity,! such! as! increased! number! of!
antigen.specific! T! cells! and! the! selective! enrichment! of! T! cell! avidity! [228]! [229].!






boosters,!with! the! nature! of! the! antigen!delivery! system!determining! its! ability! to!
boost! a! cell.mediated! immune! response.! A! priming! immunisation! with! a!
recombinant! influenza! virus! expressing! an! epitope! from! a! protein! of! P.) yoelii!




than! a! synergistic! effect! and! did! not! result! in! greatly! enhanced! effector! T.cell!
induction![233]![234].!
In! general! DNA! plasmids! are! excellent! priming! agents! but! relatively! ineffective! as!
boosting!agents,!while!MVA!and!adenovirus!strains!are!capable!of!either!priming!or!
boosting! when! used! in! heterologous! regimens.! Many! groups! have! now! reported!
enhanced!CD4+!and!CD8+!T!cell!induction!by!heterologous!prime.boost!strategies!in!
a! range! of! disease! models! (tuberculosis,! HIV,! HPV! and! Ebola)! but! is! yet! to! be!
investigated!for!C.)trachomatis![235]![236]![237]![238].!
!
In! this! chapter!we!will! comparatively! assess! the! induction! of! humoral! and! cellular!
immunity! against! C.! trachomatis! following! heterologous! prime.boost! vaccinations!




vaccination! approaches! using! regimens! encompassing! the! four! differing! vaccine!
platforms!described!in!chapter!3!should!elicit!a!spectrum!of!immune!responses,!and!
potentially!engage!both!the!humoral!and!cellular!arms!of!the!immune!system.!These!
vaccine! constructs! and! their! use! application! in! differing! regimens! will! provide! an!




• To! elicit! a! spectrum! of! immune! responses! against! MOMP,! and! potentially!
engage!both!the!humoral!and!cellular!arms!of!the!immune!system.!!
Objective!
• To! comparatively! assess! the! induction! of! humoral! and! cellular! immunity!
against!MOMP! following! heterologous! prime.boost! vaccinations! with! DNA,!
Adenovirus,!MVA!and!recombinant!protein!based!vaccines.!
• MOMP.specific! humoral! immunity! will! be! measured! by! ELISA! and! ELISA.
based!avidity!assays.!











(M)! and! a! final! recombinant! protein! adjuvanted! with! MF59! boost! (P)! would! be!
represented! as! a!DAMP! regimen.! Accordingly,! a! DNA! prime!with! two! subsequent!
DNA!boosts!all!with!electroporation!is!abbreviated!to!DDD.!All!immunisations,!unless!
otherwise!stated,!are!administered!intramuscularly!at!three!weeks!apart,!with!serum!
and!vaginal! sampling! two!weeks!after!each! immunisation.!These! timings!had!been!
previously! optimised! in! our! laboratory! in! order! to! sample! at! peak! antigen.specific!
antibody!concentrations.!Mice!were!sacrificed!one!week!after!the!final!immunisation!
to!assess!cellular!responses!from!splenocytes!(Figure!4.1A).!!!
The! vaccination! regimens! tested! were! based! off! a! matrix.like! approach! to!
encompass!as!many! iterations!as!practically! feasible!(Figure!4.1B).!DNA!and!HuAd5!
vaccines,! as! discussed! in! Chapter! 4.3,! have! been! previously! shown! to! be! good!
priming!agents,!while!MVA!vectored!vaccines!are!poor!at!priming!and! this! set! the!
basis!for!a!set!of!the!heterologous!prime.boost!regimens!investigated.!HuAd5!prime!
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to!the!difficulties!in!producing!high!yields!of!recombinant!MOMP!protein,!regimens!
without! any! recombinant! protein! was! investigated! alongside! regimens! with!
recombinant!protein!boosts.!Previous!work!in!our!laboratory!revealed!the!need!for!
two.three!initial!DNA!vaccinations!to!induce!sufficient!humoral!and!cellular!immune!




4.2.2 Antibody! immunogenicity! of! C.) trachomatis! MOMP! vaccines! in!
intramuscular!heterologous!primeWboost!regimens!
The!immunogenicity!of!a!C.)trachomatis!antigen!MOMP!was!assessed!in!BALB/c!mice!
immunised! in! heterologous! prime.boost! regimens! with! DNA,! HuAd5,! MVA! and!
protein! (+! MF59)! based! vaccines.! Immunisations! were! administered! three! weeks!
apart! and! serum! and! vaginal! washes! sampled! two! weeks! post.final! immunisation!
(Figure! 4.2A).! Peak! MOMP.specific! serum! IgG! concentrations! were! measured! as!
described!in!Chapter!2.4.4,!with!the!highest!mean!concentration!afforded!by!the!PPP!
regimen! (mean! =! 1.27!mg/ml)! and! the! lowest! from! the!DDD! regimen! (mean! =! 15!
μg/ml).!
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Table!4.1.!MOMPWspecific!serum!IgG!concentration!comparisons.!






tests! and! are! presented! in! Table! 4.1.! Regimens! (columns)! inducing! significantly!
greater!MOMP.specific! serum! IgG! concentrations! than! other! regimens! (rows)! are!
signified!by!their!degree!of!significance!(*p!≤!0.05,!**p!≤!0.005,!***p!≤!0.0005!and!
****p! ≤! 0.0001).! This! indicates! that! it! is! the! final! two! protein! (+! MF59)!
immunisations! that! significantly! increase!MOMP.specific! serum! IgG! concentrations!
above! prime.boost! regimen! without! two! protein! boosts.! The! MOMP.specific! IgG!
kinetics! following! the! differing! vaccination! regimens! are! provided! in! the! Appendix!
(Figure!9.4!&!Figure!9.5).!
Alongside! serum! measurements,! MOMP.specific! vaginal! IgG! concentrations! were!
measured! following! the! heterologous! prime.boost! vaccine! regimens.! With! a! one.
way! ANOVA! and! Bonferroni’s! multiple! comparison! post.test! analysis,! PPP! (*,! p! ≤!
0.05)! induced! significantly! higher!MOMP.specific! vaginal! IgG! than!DDDAM,!DDDA,!
DDDM,! DDD,! AM! or! the! naïve! group.! This! indicates! that! only! the! PPP! regimen!
induced!significantly!higher!vaginal!MOMP.specific!IgG!concentrations,!compared!to!
naïve!controls!and!regimen!without!protein!boosts!(Figure!4.2B).!!
Next! we! utilised! an! avidity! assay! (as! described! in! Chapter! 2.4.6)! as! a! means! to!
differentiate!and!qualitatively!evaluate!the!humoral!responses!(Figure!4.2C).!MOMP.
specific! serum! IgG!avidities! are! grouped! low,!medium!and!high!based!upon! the!%!
avidity!index.!Low!is!classified!as!<30%,!medium!is!30.50%,!and!high!avidity!are!>50%.!
All!protein! free! regimens! (DDDAM,!DDDA,!DDDM,!DDD!and!AM)!had!mean!avidity!
indices!of!<30%,!with!DDDM!having!the!lowest!mean!avidity!index!(mean!=!17.5).!In!
addition,! the! DAMP! and! PP! regimens! had! low! mean! avidity! indices,! with! these!
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regimens!only!having!a!single!protein!(+MF59)!boost.!The!regimens!with!two!protein!




specific! IgG2a! to! IgG1! ratio.!MOMP.specific! serum! IgG2a! and! IgG1! concentrations!
were!measured!by!ELISA,!and!the!ratios!calculated!(Figure!4.2D).!Mean!ratios!+!SEM!
are! represented.! The! highest!MOMP.specific! serum! IgG2a:IgG1! ratio! was! induced!
following!the!DAMP!regimen!(mean!=!14.2),!with!the!lowest!ratio!induced!following!
PP! (+! MF59)! vaccination! (mean! =! 0.0036).! ! There! was! a! significant! statistical!
difference! in! the! IgG2a:IgG1! ratios! between! DAMP! and! PPP! (**,! p! ≤! 0.005)! and!
DAMP! and! PP! (***,! p! ≤! 0.0005,! one.way! ANOVA! with! Bonferroni’s! multiple!
comparison! post.test).! Protein! only! vaccine! regimens! induced! Th2.biased! immune!
environments! indicated! by! IgG2a:IgG1! ratios! of! less! than! 1.! However,! vaccine!
regimens! with! a! vector.based! vaccine! prime! consistently! induced! a! Th1.biased,!


















MOMP.specific! IgG! from! serum! (A)! and! vaginal!washes! (B)!were! assessed! in!BALB/c!mice! (n=8!per!
group)! two! weeks! after! completion! of! the! indicated! prime.boost! regimens.! Antibody! results! are!
expressed! as! group! means! (+SEM)! (μg/ml! or! ng/ml).! The! antibody! avidity! assessment! (C)! is! the!
corresponding! serum! MOMP.specific! IgG! ELISA! using! non.reducing! (PBS)! and! reducing! (8M! urea)!
washes!after!sample!addition.!Results!are!shown!as!percentage!(%)!change!in!binding!(reducing!OD!650!/non.







4.2.3 T! cell! immunogenicity! of! C.) trachomatis! MOMP! vaccines! in!
intramuscular!heterologous!primeWboost!regimens!
T! cell! responses!were! also! assessed! in!BALB/c!mice! following!heterologous!prime.
boost!vaccine!regimens!with!DNA,!HuAd5,!MVA!and!protein!(+!MF59)!based!vaccines!
one!week!after!the!final! immunisation!(Figure!4.3).!Splenocytes!were!re.stimulated!
with! MOMP! peptides! as! described! in! Chapter! 2.4.9.! T! cell! IFN.γ! responses! were!
induced!by!all!prime.boost!regimens,!with!the!DDD!and!AM!regimens! inducing!the!
strongest! T! cell! responses,! with! a! median! of! 504! and! 502! SFU/106! splenocytes!
respectively.! ! The! T! cell! responses! induced! by! the! DDD! and! AM! regimens! were!
significantly!higher!than!those! induced! in!the!PP!regimen!(p<0.05!by!Kruskal.Wallis!
test!with!Dunn’s!multiple!comparison!post.test)!(Figure!4.3).!!
Intracellular! cytokine! staining!was! used! to! assess! the! polyfunctionality! or! cytokine!
response! profile! of! CD4+! and! CD8+! T! cells! from! the! heterologous! prime.boost!
vaccinated! BALB/c! mice.! From! these! analyses! it! was! clear! that! the! CD4+! T! cells!
displayed! a! greater! degree! of! polyfunctionality! than! the! CD8+! T! cells.! Very! low!
percentages,! if!any,!of!CD8+!T!cells!expressed!all! three!of! the!measured!cytokines,!
IFN.γ,!TNF.α!and!IL.2.!CD4+!T!cells!from!DDPP!vaccinated!mice!exhibited!the!highest!
percentage!of!polyfunctionality,!with!0.5%!of!total!CD4+!T!cells!expressing!all!three!






























































Vaccinated! BALB/c! mice! (n! =! 8! per! group)! were! sacrificed! one.week! post.final! immunisation.! (A)!
Splenocytes!were!assessed!by!IFN.γ!ELISpot!for!MOMP.reactive!T!cells!using!15.mers!overlapping!by!
11! amino! acids.! Data! is! expressed! as! group! medians! (SFU/million! antigen! stimulated! cells! (+!
interquartile! range))! *! p! ≤! 0.05! by! Kruskal.Wallis! with! Dunn’s!multiple! comparison! test.! (B! and! C)!
MOMP.reactive!splenocytes!were!assessed!for!polyfunctional!cytokine!responses!of!IFN.γ,!TNF.α!and!
Il.2.! ! CD4+! (B)! and! CD8+! (C)! T! cell! populations! were! gated! and! single,! double! or! triple! cytokine!
expressing!cell!percentage!enumerated.!The!percentage!cytokine!expression!of!each!BALB/c!mouse!





induce!2.5%!of! the!CD4+!T! cells! to!produce!TNF.α!alone! following!MOMP!peptide!





The!C.) trachomatis!MOMP!protein,! formulated!with! the!adjuvant!monophosphoryl!
lipid!A!(MPLA),!was!administered!intranasally!into!BALB/c!mice!as!a!mucosal!route!of!
delivery! to! assess! whether! enhanced! MOMP.specific! mucosal! immune! responses!
could!be!elicited.!Mucosal!immunisation!has!been!previously!shown!to!elicit!mucosal!
immune! responses,! in! particular! specific! IgA,! to! other! antigens! due! to! mucosal!
lymphoid! linkage! [240].! Immunisations! were! administered! three! weeks! apart! and!
serum!and!vaginal!washes!sampled!two!weeks!post.final!immunisation!(Figure!4.4A).!
While! the! third!protein! intranasal! immunisation!did!not! induce! significantly!higher!
MOMP.specific!serum!IgG!concentrations,! the! fourth!protein! intranasal! inoculation!
significantly! boosted!MOMP.specific! serum! IgG! concentrations! over! two! (***,!p! ≤!
0.0005)! and! three! immunisations! (**,! p! ≤! 0.005).! There! was! no! MOMP.specific!
serum!IgA!present!(Figure!4.4A).!!
Concentrations!of!MOMP.specific!vaginal! IgG!were!only!detectable! following! three!
intranasal! immunisations! (mean! =! 23.5! ng/ml)! (Figure! 4.4B).! Significantly! greater!
concentrations!(***!p!≤!0.0005,!mean!=!189.4!ng/ml)!were!induced!after!the!fourth!
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intranasal! immunisation.! Concurrently,! after! four! intranasal! immunisations!
detectable! concentrations! of! MOMP.specific! vaginal! IgA! were! induced! indicating!
that! antigen! specific! IgA!was! generated! in! the!mucosal! compartments! even!when!
absent!from!the!serum!(mean!=!48.8!ng/ml).!!
HuAd5!and!MVA!vectored! vaccines! expressing! the!MOMP! transgene!were!used! in!
adenoviral!prime.MVA!boost!regimens!(AM).!Both!these!viral!vectored!vaccines!can!
infect!through!the!mucosa,!and!thus!were!administered!both!intranasally!(I.N.)!and!
intravaginally! (I.Vag.)! and! compared! to! intramuscular! (I.M.)! injections.!!
Immunisations!were!administered!three!weeks!apart!and!serum!and!vaginal!washes!
sampled! two! weeks! post.final! immunisation! (Figure! 4.4C).! I.M.! AM! (mean! =! 46.4!
μg/ml)! induced!significantly!greater!MOMP.specific! serum! IgG!concentrations! than!
both!I.Vag.!AM!(*!p!≤!0.05,!mean!=!0.06!μg/ml)!and!I.N!AM!(*!p!≤!0.05,!mean!=!3.7!
μg/ml).! I.M.!AM!was! the!only! route!and! regimen! to! induce!vaginal!MOMP.specific!
IgG! (mean! =! 34.9! ng/ml)! and! the! specific.IgG! concentrations! were! significantly!














MOMP.specific! IgG! and! IgA! from! serum! (A)! and! specific! IgG! and! IgA! from!vaginal!washes! (B)!were!
assessed! in! BALB/c! mice! (n! =! 8! per! group)! two! weeks! after! each! MOMP+MPLA! intranasal!
immunisation.!MOMP.specific!IgG!from!serum!and!vaginal!washes!(C)!were!assessed!in!BALB/c!(n!=!8!
per! group)! two!weeks! after! Adenoviral! prime.MVA! boost! by! the! intranasal! route,! the! intravaginal!
route!or! the! intramuscular! route.!Antibody! results!are!expressed!as!group!means! (+SEM)! (μg/ml!or!































4.2.5 T! cell! immunogenicity! of! C.) trachomatis! MOMP! vaccines! following!
mucosal!application!in!primeWboost!regimens!
T!cell! responses!were!assessed! in!BALB/c!mice! following! intranasal!PPPP! (+!MPLA)!
immunisation!one!week!after!the!final!immunisation!(Figure!4.5A).!Splenocytes!were!
re.stimulated! with! MOMP! peptides! as! described! previously.! Low! T! cell! IFN.γ!
responses!were!induced!by!intranasal!PPPP!(+!MPLA),!with!a!median!of!48!SFU/106!
splenocytes,! compared! to! a! median! of! 39! SFU/106! splenocytes! for! unvaccinated!
naïve!BALB/c.!!There!was!no!statistical!difference!between!intranasal!PPPP!(+!MPLA)!
and! unvaccinated! controls! (Kruskal.Wallis! test! with! Dunn’s! multiple! comparison!
post.test).!Intracellular!cytokine!staining!was!used!to!assess!the!polyfunctionality!or!
cytokine! response! profile! of! CD4+! and! CD8+! T! cells! from! the! intranasal! PPPP! (+!
MPLA)! vaccinated! BALB/c! mice.! MOMP.specific! CD4+! T! cells! were! poorly!
polyfunctional,! with! 0.6%! of! MOMP.reactive! CD4+! T! cells! expressing! just! TNF.α.!
MOMP.specific! CD8+! were! polyfunctional! for! IFN.γ! and! TNF.α,! with! 0.4%! of! the!
reactive!CD8+!cells!expressing!both!together.!!
T! cell! responses! were! also! assessed! in! BALB/c! mice! following! intranasal! (I.N.),!
intravaginal!(I.Vag.)!and!intramuscular!(I.M.)!adenoviral!prime.MVA!boost!regimens!
(AM)! one! week! after! the! final! immunisation! (Figure! 4.5B).! Splenocytes! were! re.
stimulated!with!MOMP!peptides!as!described!previously.!Low!T!cell!IFN.γ!responses!
were! induced! by! both! intranasal! and! intravaginal! routes! of! immunisation,! with! a!
















































one! week! after! the! final! immunisation.! Splenocytes! were! assessed! by! IFN.γ! ELISpot! for! MOMP.
reactive! T! cells! using! 15.mers! overlapping! by! 11! amino! acid.! Data! is! expressed! as! group! means!
(SFU/million! antigen! stimulated! cells! (+! SEM)).! MOMP.reactive! splenocytes! were! assessed! for!
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polyfunctional!cytokine!responses!of! IFN.γ,!TNF.α!and! Il.2.! !CD4+!and!CD8+!T!cell!populations!were!




MVA!boost! immunisations!via!alternate! immunisation! routes! including! intranasal! (I.N.),! intravaginal!
















splenocytes.! ! There! was! a! statistical! difference! between! the! intranasal! and!
intramuscular! route! of! immunisation! for! adenoviral! prime.MVA! boost! regimens!
(AM)! in!the! induction!of!T!cell! IFN.γ!responses!(*!p!≤!0.05,!Kruskal.Wallis! test!with!
Dunn’s!multiple! comparison! post.test).! Intracellular! cytokine! staining! was! used! to!
assess! the!polyfunctionality! or! cytokine! response!profile! of! CD4+!and!CD8+!T! cells!
from! the! intranasally! (I.N.),! intravaginally! (I.Vag.)! and! intramuscularly! (I.M.)!
immunised! adenoviral! prime.MVA! boost! regimens! (AM)! in! BALB/c! mice.! MOMP.
specific!CD4+!and!CD8+!T!cells!were!poorly!polyfunctional! irrespective!of!the!route!
of!immunisation!for!the!AM!regimens.!CD4+!T!cells!were!monofunctional!for!either!
TNF.α!or! IL.2! following! intranasal!and! intravaginal! immunisation,!with!CD8+!T!cells!
being!monofunctional!for!IFN.γ!following!intranasal!and!intravaginal!immunisation.!!
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DDDAM! +! +! ! ++! ND!
DDDA! ! ! ! !
DDDM! ! ! ! !
DDD! ! ! ! +++!
AM! ! ! ! +++!
DAMP! ++! ++! ! ! ++!
AMPP! +++! +++! ! ++! ++!
DDPP! ++! ++! ! ! +++!
APP! +++! +++! ! ! +!
PPP! +++! +++! ! ! !
PP! ++! ++! ! ! !
PPPP!+!MPLA!
(I.N).!
++! ++! +! ! !
AM!(I.N.)! ! ! ! ! !
AM!(I.Vag.)! ! ! ! ! !
!
Table!4.2.!Regimen!screening!immune!outcomes!in!BALB/c!mice.!








potential! chlamydia! vaccine! candidates,! with! the! majority! of! chlamydia! vaccine!
research! concentrating! on! homologous! prime.boost! strategies.! One! heterologous!
study! examined! the! immune! response! induced! by! recombinant! adenovirus!
expressing!the!chlamydia!antigen!CPAF!(Chlamydia!Protease.like!Activity!Factor)!and!
recombinant! CPAF! subunit! vaccines,! adjuvanted! with! CpG! and! the!
immunomodulatory! peptide!HH2.! The! heterologous! adenovirus! prime! and! protein!
boost! induced!a!Th1.biased!cellular! immune!response,!while!the!homologous!CPAF!
subunit! induced! a! more! mixed! Th1/Th17! profile.! Despite! these! disparities! in! the!
regimen,! both! the! heterologous! and! homologous! prime.boost! regimens! conferred!
significant!protection!against!genital!C.)muridarum!challenge!in!BALB/c!and!C3H/HeN!
mice! [153].! Another! chlamydial! heterologous! prime.boost! vaccination! strategy!
involved!DNA!priming!and!protein!boosting!with!the!chlamydial!protein!CT043.!This!
regimen! resulted! in! a! 2.6.log! reduction! in! the! IFU! in! a! murine! chlamydia! lung!
infection!model![241].!!
There!have!been!previous!attempts!to!use!DNA!vaccines!against!Chlamydia,!though!
in! contrast! to! our! current! study! none! of! these! have! been! administered! with!
electroporation.! In! one! study,! intramuscular! DNA! immunisation! with! either! the!
MOMP!gene!or!the!cytosine!triphosphate!synthetase!(CTP)!gene!was!investigated!in!





on!C.) trachomatis!MOMP! against! genital!C.) trachomatis! infection! in! their! recently!
developed!pig!model.!When!administering!the!DNA!vaccine!to!the!vaginal!mucosa,!a!
cellular! immune! response!was! induced!alongside! significant!protection! in!pigs,! yet!
infection! could! not! be! cleared! completely! [155].! When! the! DNA! vaccine! was!
administered!to!both!the!nasal!and!vaginal!mucosa!of!the!pig,!cellular!and!humoral!
immune! responses! were! induced! concurrently,! and! this! immunity! afforded!
significant!protection!to!the!pigs!against!a!genital!C.)trachomatis!infection![243].!
A! literature! review! revealed! only! one! previous! use! of! an! adenovirus.vectored!
vaccine! against! Chlamydia! in! the! mouse! model.! This! involved! priming! with! the!
recombinant! adenovirus! vector! expressing! CPAF! prior! to! a! recombinant! protein!
boost,! as! described! earlier! [153].! Lu! et) al.,! transfected! dendritic! cells! with!
recombinant! adenovirus! expressing! the!C.) trachomatis! serovar! E!MOMP!gene! and!
observed! an! increased! expression! of! CD80! and! enhanced! IL.12! secretion! and! the!
increased! secretion! of! IFN.γ! from! stimulated! T! cells.! When! the! Ad.MOMP!
transfected! DCs! were! adoptively! transferred! intravenously! into! naive! mice,! they!
generated! Th1.biased! cytokines! and! mucosal! IgA! responses! specific! for! C.)
trachomatis.! Furthermore,! following! the! adoptive! transfer! the! mice! mounted!
protection!against!genital!tract!challenge!infection,!with!lower!body!mass!loss,!lower!
chlamydial! loads! and! less! severe!pathology! [244].!One!other! viral! vector!has!been!
utilised,!with!a!poliovirus!used!to!express!a!MOMP.epitope.!A!poliovirus!hybrid!was!
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constructed! from! poliovirus! type! 1!Mahoney,! expressing! the! variable! domain! I! of!
MOMP! of! C.) trachomatis! serovar! A,! and! rabbit! antisera! raised! against! this! hybrid!
neutralised! chlamydia! infection! in) vitro.! Moreover,! this! antisera! when! passively!





Within!our!studies!we! investigated!the!avidity!of! the!anti.MOMP!antibodies! raised!
following! the! differing! prime.boost! regimens.! There! can! be! more! to! antibody.
mediated! protection! than! the! peak! of! vaccine.induced! antibody! titres,! with! the!
quality! of! such! antibody! responses,! such! as! their! avidity,! identified! as! a! potential!
determining! factor! of! efficacy.! For! meningococcal! C! vaccines! only! high.avidity!
antibodies!are!bactericidal,!and!conjugate!vaccines!against!Streptococcus!pneumonia!
and!Haemophilus! influenza! type!b! (Hib)! specifically! induce!an! increase! in! antibody!
avidity![246]![247]![248].!Furthermore,!low!concentrations!of!passively!infused!high.
avidity! antibody! can! protect! experimentally! infected! animals! from! these! diseases!
[249]! [250],!with!avidity! likely!playing!a! role! in! the!antibody’s!neutralisation!ability!
[251].! At! the! date! of! writing,! no! publically! accessible! publications! have! examined!
anti.MOMP!polyclonal!antibody!avidities.!Our!data!suggests!that!two!protein!boosts!
are! required! to! push! the! antibody! avidities! into! a! medium! to! high! category! as!
assessed! by! the! urea! denaturation! avidity! ELISA! assay,!with! protein.free! regimens!
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inducing!consistently!low!avidity!anti.MOMP!antibodies.!
The! polyfunctionality! of! the! T! cells! following! vaccination! were! investigated.!
Polyfunctional! CD4+! T! cells! are! a! characteristic! of! HIV.controllers! [252],! and! in!
mouse! models,! vaccine.induced! polyfunctional! CD4+! T! cells! correlate! with!




as! in! producing! high! amounts! of! cytokines! [256].! T! cell! polyfunctionality! has! only!
been! analysed! for! one! chlamydia! vaccine! to! date.! Following! subcutaneous!
immunisation! with! the! chlamydia! proteins! CT144! and! CT823! with! the! adjuvant!
AbISCO.100,! the! CD4+! polyfunctionality! for! IL.10,! TNF.α! and! IL.2!was! investigated!
[257].!T!cells!from!the!spleen!and!mediastinal!lymph!nodes!(MdLN)!of!mice!that!had!
been! vaccinated! with! MOMP! co.formulated! with! differing! adjuvants! and!
administered!by!differing!routes!were!harvested!and!restimulated!with!recombinant!
MOMP!antigen.!The!bulk!production!of!IFN.γ,!TNF.α,!IL.4,!IL.10!and!IL.17!from!these!
stimulation! cultures! was! assessed! using! a! Luminex.type! assay! but! the!
polyfunctionality!of!individual!T!cells!was!not!investigated![258].!!
!
From! our! results! it! is! apparent! that! DNA! priming! induces! the! greater! CD4+! T! cell!
polyfunctionality,!with!HuAd5!priming!also!affording!some!increase!in!polyfunctional!





in!over!90%!of! vaccinees,!with!only!33%! responding! to! the!NYVAC!alone! regimen.!
These! T! cell! responses! from! DNA! priming! were! of! a! polyfunctional! cytokine!
phenotype!for!both!CD4+!and!CD8+!T!cells,!and!durable!for!up!to!72!weeks![259].!For!
hepatitis! C,! it! was! a! DNA! prime! and! MVA! boost! regimen! that! was! capable! of!
activating! quadrifunctional! T! cells! (IFN.γ/TNF.α/CD107a/IL.2)! in!mice,! and! showed!
protection!in!a!Listeria.NS3.1a!challenge!model![260].!
!
Another! potential! correlate! of! protection! that! we! analysed! following! the!
heterologous!prime!boost!regimen!was!the!MOMP.specific!IgG!isotypes,!in!particular!
IgG2a!and!IgG1.!An!IgG2a:IgG1!ratio!of!>1!is!associated!with!a!Th1!response,!while!a!










titre!of!160! in!BALB/c!mice! [261],!while!MOMP!adjuvanted!with! cholera! toxin!and!





point! titre! of! approximately! 10,000! (Dr.! McKay,! personal! communication).! This!
would! suggest! the! antibody! levels! induced! in! our! studies! being!much! higher! than!
those!of!these!previous!studies.!!!!
!





specific! IFN.γ! SFU/106! splenocytes! [263].! Alternative! chlamydial! antigens! have!
afforded! greater! IFN.γ! ELISpot! responses.! The! PmpG! antigen! adjuvanted! with!
AbISCO®! resulted! in! over! 1000! IFN.γ! secreting! splenocytes! per!million! cells! [264],!





mean! MOMP.specific! vaginal! IgA! concentrations! of! 49! ng/ml.! None! of! the!
intramuscular!routes!of!immunisation!nor!the!mucosal!application!of!HuAd5!or!MVA!
were!capable!of!inducing!MOMP.specific!vaginal!IgA!in!our!studies.!Singh!et)al.!were!
capable!of! inducing!MOMP.specific! IgA! systemically!and!vaginally!by!administering!
the! recombinant! MOMP! protein! intranasally! with! the! mucosal! adjuvant! cholera!
toxin! [265].! Furthermore,! Vibrio! cholera! ghosts! expressing!MOMP! and! the! HSV.2!
glycoprotein!D!were!capable!of!eliciting!secretory!IgA!to!both!antigens!in!serum!and!
vaginal!secretions!following!intramuscular!immunisation![266].!These!studies!reveal!




The! AM! regimen! via! mucosal! surfaces! was! a! poor! inducer! of! MOMP.specific!
responses.! Neither! the! AM! regimen! via! the! intranasal! nor! the! intravaginal! route!
induced!antigen.specific!humoral!or!cellular!responses.!There!are!no!publications!in!
which! the!AM!regimen! is!exclusively!used!on!mucosal! surfaces,!often! instead!with!
the!adenoviral!prime!being!intramuscular![267].!However,!BALB/c!mice!intranasally!
immunised!with!just!one!shot!of!rAd!expressing!the!G!protein!of!RSV!induced!strong!
serum! antibodies! [268],! and! an!MVA! expressing! HIV.1! Env! inoculated! intranasally!
induced! significant! immune! responses! to! the!HIV.1! antigen.!However,! intravaginal!
inoculation! of! the!MVA.Env!was! not! immunogenic! [269].! These! successful! uses! of!
mucosal! immunisations!by!viral!vectors! suggests! that! the!poor! immunogenicity!we!
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observed!may!be!a!MOMP.specific! issue,!or!potentially!due!to!the!timing!between!
prime.boost! immunisations.! ! Reyes.Sandoval!et!al.! observed! polyfunctional! T! cells!
with!strong!IFN.γ!production!following!an!AM!regimen!for!malarial!antigens,!with!8!
weeks!between! the!prime!and!boost! as! opposed! to!our! 3.week! interval! [91].! This!
timing! may! be! important! for! T! cell! contraction! and! maturation! of! the! immune!
response.!!!
We!set!out!to!comparatively!assess!the!induction!of!humoral!and!cellular!immunity!
against! MOMP! following! heterologous! prime.boost! vaccinations! with! DNA,!
Adenovirus,!MVA!and!recombinant!protein!based!vaccines.!Taken!all! together,! this!
chapter! revealed! a! capability! to! induce! an! array! of! MOMP.specific! immune!
responses,!both!cellular!and!humoral,!using!the!four!differing!MOMP.based!vaccines!
in!heterologous!prime.boost!regimens.!Protein!boosting!significantly!increased!both!
serum! and! vaginal! antibody! concentrations,! while! DNA! and! viral! vector! alone!
regimens! induced! the! greatest! cellular! responses! as! analysed! by! IFN.γ! ELISpot.!
Protein!boosts!increased!the!avidity!of!the!induced!specific.serum!antibodies,!while!
CD4+!T!cell!polyfunctionality!was!broadest! following! regimens!with!DNA!or!HuAd5!
prime.! The! regimens! will! be! grouped! according! to! the! distinct! MOMP.specific!
immune! environments! they! elicit,! and! in! the! subsequent! chapters! taken! through!


























the! female! mouse! genital! tract! is! susceptible! to! infection! with! both! Chlamydia)
muridarum! [120]! and! Chlamydia) trachomatis! [121]! strains! resulting! in! the!
establishment!of! two!murine!models;! the!C.) trachomatis!mouse!model! and! the!C.)
muridarum!mouse!model.!!
C.)muridarum!(also!termed!C.)trachomatis!MoPn)!is!a!natural!mouse!pathogen!that!
causes! pneumonitis! and! was! originally! isolated! from! the! lungs! of! mice! [270].!
Intravaginal! inoculation!of!C.)muridarum! in!mice! results! in!a! genital! tract! infection!
that!closely!resembles!acute!genital!C.)trachomatis!infections!in!women![120].!Mice!
generally! resolve! the!genital! tract! infection!within!4!weeks,!after! the! infection!has!
ascended!to!the!uterine!horns!and!oviducts!and!resulted!in!hydrosalpinx.!
Mice! can! also! be! genitally! infected! with! human! C.) trachomatis! serovars! [121].!





in! the! mouse! model! [124]! [271]! [272].! Infection! by! vaginal! inoculation! normally!
resolves! without! complications! [273]! [274]! [275].! Lyons! et) al.! argue! that! the!
infection! of! mice! with! C.) trachomatis! mimics! in! many! ways! both! the! course! and!
outcome!of! infection! in!most!women!–!an!asymptomatic!and!self.limiting! infection!
that!only!rarely!results!in!severe!upper!genital!tract!disease![128].!This!was!a!strong!




C.)trachomatis!serovar!E! infection!has!a!significantly! longer!duration!of! infection! in!
C3H/HeN!mice!than!in!C57BL/6![273].!C57BL/6,!BALB/c!and!CF.1!mice!infected!with!
C.) trachomatis! serovar! D! resulted! in! BALB/c! mice! having! significantly! shorter!
durations!of!infection!than!either!C57BL/6!or!CF.1.!However,!C57BL/6!and!CF.1!mice!
shed! significantly! less! chlamydia! than! BALB/c! mice! during! the! first! 2! weeks! of!
infection![108].!









In! this! chapter! we! aim! to! assess! the! protective! capacity! of! MOMP.based!
heterologous!prime.boost! regimens!against!vaginal!C.) trachomatis! infection! in! two!
differing!mouse!models!and!to!investigate!the!mechanism!of!the!vaccine!induced!C.)




have! been! shown! to! confer! protection! to! secondary! chlamydial! infections! [262]!
[105]! [117].! A! role! of! CD8+! T! cells! in!murine! genital! chlamydial! immunity! has! not!
been!convincingly!shown!to!date,!with!CD8+!T!cell!depletions!having!no!significant!
effect! on! bacterial! loads! during! primary! nor! secondary! infections! [277]! [278].! In!
assessing!the!potential!humoral!contribution!to!protection,!the!role!of!antibody!will!




• To! reveal! a! MOMP.based! vaccination! regimen! which! protects! against!
intravaginal!C.)trachomatis!infection!in!mice.!!




• Assess! the! protective! capacity! of! MOMP.based! heterologous! prime.boost!
regimens! against! vaginal! C.) trachomatis! infection! in! BALB/c! and! B6C3F1!




• Assess! the! role! of! MOMP.specific! antibodies! in! the! vaccine.induced!
protection!by!passively!infusing!serum!from!vaccinated!mice!into!naïve!mice,!
prior!to!intravaginal!C.)trachomatis!infection.!!
• Assess! the! role! of! MOMP.specific! antibodies! from! the! protective! vaccine!
regimen!in!an! IFN.γ.deficient!environment!by!passively! infusing!serum!from!
vaccinated! mice! into! naïve! IFN.γ.receptor! knock.out! mice,! prior! to!
intravaginal!C.)trachomatis!infection.!
• Assess! the! role! of! antibody.mediated! neutralisation! in! the! protection!







5.2.1 C.)trachomatis! serovar!D!shedding!profiles! following!primary!vaginal!
infection!of!BALB/c!and!B6C3F1!mice!
Two!mouse!strains!used!for!the!screening!of!C.)trachomatis!vaccines!include!BALB/c!







6500! IFU! per! swab! respectively.! With! sampling! every! 3! days! for! 15! days,! the!
chlamydial! load!continued!to!decrease.!At!the!final!sampling!time!point!of!15!days!
post!challenge,!BALB/c!and!B6C3F1!mice!had!a!median!of!25!and!13! IFU!per!swab!
respectively.! For! each! sampling! time! point! there! was! large! variation! in! the!
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5.2.2 Intramuscular! heterologous! primeWboost! C.) trachomatis! MOMP!
vaccine! regimens! elicit! different! immune! responses! in! BALB/c! and!
B6C3F1!mice!!!
The! C.) trachomatis! antigen! MOMP! was! assessed! in! B6C3F1! mice! immunised! in!
heterologous!prime.boost!regimens!(Table!5.1)!with!DNA,!HuAd5,!MVA!and!protein!
(+!MF59)!based!vaccines!and!compared!against!their!immunogenicity!in!BALB/c!mice!
(Figure! 5.2).! Immunisations! were! administered! three! weeks! apart! and! serum! and!
vaginal! washes! sampled! two! weeks! post.final! immunisation.! The! DAMP! regimen!
induced! significantly! higher! MOMP.specific! serum! IgG! concentrations! in! B6C3F1!
mice!than!in!BALB/c!mice!(***!p!≤!0.0005,!2.way!ANOVA!with!Bonferroni’s!multiple!
comparisons!test),!with!respective!means!of!1796!μg/ml!and!258!μg/ml.!AMPP!also!
induced! significantly! higher! MOMP.specific! serum! IgG! concentrations! in! B6C3F1!
mice! than! in! BALB/c! (*! p! ≤! 0.05,! 2.way! ANOVA! with! Bonferroni’s! multiple!
comparisons! test)! with! respective! means! of! 1733! μg/ml! and! 741! μg/ml.! The!
regimens!AM,!DDD,!PPP!and!naïve!controls!did!not!significantly!differ!in!their!mean!
MOMP.specific!serum!IgG!concentrations!between!B6C3F1!and!BALB/c!mice.!!!
There! were! no! statistically! significant! differences! in! MOMP.specific! vaginal! IgG!
concentrations! between! B6C3F1! and! BALB/c! mice! for! any! of! the! regimen!
investigated!(2.way!ANOVA!with!Bonferroni’s!multiple!comparisons!test).!!





































MOMP.specific! IgG! from! serum! and! vaginal! washes! were! assessed! two! weeks! after! prime.boost!
regimens!in!both!BALB/c!(n!=!8)!and!B6C3F1!(n!=!8)!mice!(A).!Antibody!results!are!expressed!as!group!













significantly! higher! IgG2a:IgG1! ratios! than! the! PPP! regimen! (Kruskal.Wallis! test,!
Dunn’s!multiple!comparisons!test).!!
T!cell!responses,!analysed!1!week!after!the!final!immunisation,!were!also!assessed!in!
B6C3F1! mice! following! heterologous! prime.boost! vaccine! regimens! with! DNA,!
HuAd5,!MVA! and! protein! (+!MF59)! based! vaccines! and! compared! against! BALB/c!
mice!(Figure!5.2C).!B6C3F1!splenocytes!were!re.stimulated!with!MOMP!peptides!as!
described! previously.! T! cell! IFN.γ! responses! were! induced! by! all! prime.boost!
regimens,!with!the!DAMP!and!DDD!regimens!inducing!the!strongest!T!cell!responses,!
with! a! median! of! 2580! and! 3190! SFU/106! splenocytes! respectively.! The! T! cell!
responses! induced!by! the!DAMP! (****!p! ≤!0.0001),!DDD! (****!p! ≤!0.0001),!AMPP!
(***!p!≤!0.0005),!and!AM!(**!p!≤!0.005)!regimens!were!significantly!higher!in!B6C3F1!














compared! to! unvaccinated! controls! (median! =! 34788! IFU/swab)! (*! p) =! 0.0303,! 2.
tailed!Mann.Whitney! test).! ! The!PPP! regimen!also! significantly! reduced!chlamydial!
IFU! per! swab! at! day! 3! post! challenge! (median! =! 8095! IFU/swab)! compared! to!
























Six! weeks! after! the! final! vaccination! and! 1! week! after! 2! mg/mouse! subcutaneous! Depo.Provera!
treatment,! B6C3F1!mice! (n! =! 5! to! 8)!were! infected! intravaginally!with! 4x105! IFU! of!C.) trachomatis!
D/UW.3/Cx.!The!vaginal!vault!of!each!mouse!was!sampled!using!individual!swabs!at!3,!7,!10!and!14!
days!post!challenge,!and!vaginal!Chlamydial!loads!quantified!by!infection!assay!and!immunoflorescent!






5.2.4 Percentage! of! B6C3F1!mice! shedding! following! heterologous! primeW
boost!vaccine!regimens!
At! day! 3,! 7,! 10! and! 14! post! challenge,! the! number! of! B6C3F1! mice! shedding! C.)
trachomatis! was! assessed! via! the! infectivity! based! assay! from! the! vaginal! swabs!
(Figure!5.4).!All! naïve!mice!were! shedding!up! to!day!7,!before!a! reduction! to!only!
20%!shedding!at!day!10!and!day!14.!None!of!the!assessed!vaccination!regimens!had!




























Six! weeks! after! the! final! vaccination! and! 1! week! after! 2! mg/mouse! subcutaneous! Depo.Provera!
treatment,! B6C3F1!mice! (n! =! 5! to! 8)!were! infected! intravaginally!with! 4x105! IFU! of!C.) trachomatis!
D/UW.3/Cx.!The!vaginal!vault!of!each!mouse!was!sampled!using!individual!swabs!at!3,!7,!10!and!14!
days!post!challenge,!and!vaginal!Chlamydial!loads!quantified!by!infection!assay!and!immunoflorescent!
microscopy.! Mice! are! designated! non.shedding! when! below! the! limit! of! detection! (6! IFU/swab).!
Shedding! curve! differences! were! analysed! by! both! the! Log.rank! (Mantel.Cox)! test! and! Gehan.
Breslow.Wilcoxon!test.!
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5.2.5 Assay!used! to!measure!C.) trachomatis! shedding:!Droplet!digital!PCR!
(ddPCR)!compared!to!infectivity!assay!
Vaginal! swabs! from! days! 7! and! 14! post! challenge! were! analysed! by! ddPCR! as! a!
comparison!to!the!infectivity!based!assay!from!which!the!shedding!data!is!calculated!
(Figure!5.5).! The!ddPCR!assay! is!detailed! in!Chapter!2.2.13.!ddPCR!measures!exact!
copies!of!chlamydial!genes!(omcB) in!this!case)!and!is! independent!of!the!infectivity!
of! the! shed! bacterium.! ddPCR! was! carried! out! to! investigate! whether! chlamydial!
loads!remained!high!even!though!infectivity!diminished!as!revealed!by!the!infectivity!
assay.!OmcB!copies! followed!the!same!trend!as!the! infectivity!assay.!At!day!7!post!
challenge,! the!median! copies! of!omcB! per! swab! for! the! regimens!DAMP,! PPP! and!
unvaccinated! controls! were! 17094,! 12800,! and! 5272! respectively.! At! day! 14! post!
challenge,! the!median! copies! of!omcB! per! swab! for! the! regimens!DAMP,! PPP! and!
unvaccinated!controls!were!6,!6!and!6!respectively!(lowest!limit!of!detection!of!the!
assay).! This! similar! trend! between! ddPCR! chlamydial! copies! and! the! chlamydial!

















Figure! 5.5.! Vaginal! C.) trachomatis! load! post! vaccination! as! determined! by! droplet! digital! PCR!
(ddPCR).!!

































Only! two! of! the! five! investigated! regimens! provided! protection! to! vaginal! C.)
trachomatis! infection! in! BALB/c!mice! (Figure! 5.6).! The!DAMP! regimen! significantly!
reduced!chlamydial! IFU!per!swab!at!day!3!post!challenge!(median!=!354!IFU/swab)!
compared! to! unvaccinated! controls! (median! =! 22688! IFU/swab)! (*! p! =! 0.0359,! 2.
tailed!Mann.Whitney!test).!!The!AMPP!regimen!also!significantly!reduced!chlamydial!
IFU! per! swab! at! day! 3! post! challenge! (median! =! 2563! IFU/swab)! compared! to!
unvaccinated! controls! (median! =! 22688! IFU/swab)! (*! p! =! 0.0447,! 2.tailed! Mann.
Whitney!test).!There!was!no!statistical!difference!at!the!later!time!points!of!7,!10!and!
14!days!post!challenge!due!to!the!resolution!of!infection!by!the!unvaccinated!naïve!














Six! weeks! after! the! final! vaccination! and! 1! week! after! 2! mg/mouse! subcutaneous! Depo.Provera!
treatment,! BALB/c!mice! (n! =! 7! to! 10)!were! infected! intravaginally!with! 4x105! IFU! of!C.trachomatis!
D/UW.3/Cx.!The!vaginal!vault!of!each!mouse!was!sampled!using!individual!swabs!at!3,!7,!10!and!14!
days!post!challenge,!and!vaginal!Chlamydial!loads!quantified!by!infection!assay!and!immunoflorescent!






5.2.7 Percentage! of! BALB/c!mice! shedding! following! heterologous! primeW
boost!vaccine!regimens!
At! day! 3,! 7,! 10! and! 14! post! challenge,! the! number! of! BALB/c! mice! shedding! C.)
trachomatis! was! assessed! via! the! infectivity! based! assay! from! the! vaginal! swabs!
(Figure! 5.7).! 80%! of! naïve! unvaccinated! mice! were! shedding! at! day! 7,! with! a!
reduction! to! only! 30%! shedding! at! day! 10.! None! of! the! assessed! vaccination!
regimens!had!a!statistically!significant!difference!in!the!shedding!curves!compared!to!
























Figure!5.7.!Percentage!of!BALB/c!mice! shedding!C.) trachomatis! following!vaccination!with!primeW
boost!regimens.!!
Six! weeks! after! the! final! vaccination! and! 1! week! after! 2! mg/mouse! subcutaneous! Depo.Provera!
treatment,! BALB/c!mice! (n! =! 5! to! 8)! were! infected! intravaginally!with! 4x105! IFU! of!C.) trachomatis!
D/UW.3/Cx.!The!vaginal!vault!of!each!mouse!was!sampled!using!individual!swabs!at!3,!7,!10!and!14!
days!post!challenge,!and!vaginal!Chlamydial!loads!quantified!by!infection!assay!and!immunoflorescent!
microscopy.! Mice! are! designated! non.shedding! when! below! the! limit! of! detection! (6! IFU/swab).!
Shedding! curve! differences! were! analysed! by! both! the! Log.rank! (Mantel.Cox)! test! and! Gehan.
Breslow.Wilcoxon!test.!



































































































Vaginal! Chlamydial! loads! quantified! by! infection! assay! and! immunoflorescent!microscopy! at! day! 3!
post!challenge.!Groups!include!DAMP!vaccination!(n!=!7)!and!naïve!controls!(n!=!5)!for!B6C3F1!mice!
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5.2.9 CD4+! T! cells! contribute! to! the! DAMP! regimen! vaccineWinduced!
protective!response.!
In!an!effort! to!elucidate! the! role!of!CD4+!T! cells! in! the!vaccine.induced!protective!
response,! monoclonal! antibodies! were! used! to! deplete! CD4+! cells! in! DAMP!
vaccinated! and! unvaccinated! control! B6C3F1! mice! (Figure! 5.9).! The! CD4+! T! cell!
depletion! is!detailed! in!Chapter!2.4.11.! !The!significant! reduction! in!C.) trachomatis!
shedding!in!undepleted!B6C3F1!(*!p!=!0.0303,!2.tailed!Mann.Whitney!test)!was!lost!
when!CD4+!T!cells!were!depleted.!Following!CD4+!T!cell!depletion,!DAMP!vaccinated!
B6C3F1!mice! had!median! chlamydial! loads! of! 46888! IFU/swab!while! unvaccinated!
depleted! B6C3F1! had! median! loads! of! 15675! (N.S.! p! =! 0.1638,! 2.tailed! Mann.
Whitney! test).! Thus,! CD4+! T! cells! contribute! significantly! to! the! vaccine.induced!

























B6C3F1!mice!were! depleted! of! CD4+! T! cells! by! i.p.! injections! of! 500! μg/mouse! of! anti.mouse! CD4!
monoclonal!antibody!(clone!GK1.5)!on!days!.1!and!+1!with!respect!to!day!of!challenge!day!0.!Day!3!
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5.2.10 Serum! antibody! neutralisation! ability! does! not! contribute! to! the!
DAMP!regimen!vaccineWinduced!protective!response!
One! immunological! mechanism! that! could! potentially! contribute! to! Chlamydia!
immunity! is! the!elicitation!of!antibodies!that!neutralise!EB!cell!entry.!The!ability!of!
anti.MOMP!antibodies! from!the!heterologous!prime.boost! regimens! to!prevent!EB!
infection!of!McCoy!cells! in)vitro!was!therefore! investigated,!with!the!neutralisation!
assay! fully! detailed! in! Chapter! 2.5.7.! The! DAMP,! AMPP! and! PPP! regimens! have!
similar!neutralisation!profiles!with!mean!neutralisation!abilities!of!50.60%!at!a!1/10!
serum!dilution,!dropping!to!40.45%!at!1/20!and!~30%!at!1/40!serum!dilutions!(Figure!
5.10).! The! regimens! without! the! protein! boosts,! AM! and! DDD! had! mean!
neutralisation!abilities!of!around!20%!at!1/20!and!only!10%!at!1/40!serum!dilutions,!
perhaps! reflective! of! the! lower! quantity! of! antigen.specific! anti.MOMP! per! unit!
serum.! Interestingly,! the! AM! and! DDD! regimen! differed! greatly! in! their! mean!
neutralisation! ability! at! a! 1/10! serum! dilution,! with! AM! exhibiting! similar!
neutralisation!abilities!as!DAMP,!AMPP!and!PPP!(43%),!but!DDD!only!having!a!mean!
neutralisation! ability! of! 16%.! ! The! comparable! neutralisation! profiles! of! the!
protective! DAMP! regimen! and! the! non.protective! regimens! AMPP,! PPP! and! AM!

















Figure! 5.10.! Comparable! serum! neutralisation! ability! between! protective! and! nonWprotective!
vaccine!regimens.!!
Serum! antibodies! from! the! differing! prime.boost! regimens!were! pre.incubated! at! varying! dilutions!
with!infectious!C.)trachomatis!elementary!bodies!(EBs)!and!used!to!infect!McCoy!cell!monolayers!and!
compared!with!EBs!treated!with!corresponding!dilutions!of!naïve!sera.!The!antiserum!neutralisation!
activity! was! determined! by! measuring! the! reduction! of! the! number! of! inclusions! generated! by!
antibody.opsonised! EBs! after! correction! to! the! background! inhibition! observed! with! naïve! sera!
controls.!!!
!
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5.2.11 Serum! antibodies! do! not! contribute! to! the! DAMP! regimen! vaccineW
induced!protective!response!
To!assess! the! role!of! vaccine! induced!antibodies! via! the!DAMP!and!PPP! regimens,!
serum! from! these! vaccinated!mice! were! passively! transferred! into! naïve! C57BL/6!
mice! (Figure!5.11).!15!μg!of!anti.MOMP!serum!IgG!was! intravenously! injected! into!
each!mouse,! 4! hr! prior! to!C.) trachomatis! vaginal! challenge.!Naïve! serum!was! also!
intravenously! injected! for! the! naïve! control.! There! was! no! statistically! significant!
reduction!in!C.)trachomatis!vaginal!load!at!day!3,!6!or!10!post!challenge!in!C57BL/6!
mice! for! any! of! the! serum! transfused! groups! (Kruskal.Wallis! test! with! Dunn’s!
multiple! comparison! post.test).! To! assess!whether! the! vaccine! induced! antibodies!
via! the! DAMP! and! PPP! regimens! may! have! a! greater! effect! in! an! IFN.γ! deficient!
environment,!serum!from!these!vaccinated!mice!were!also!passively!transferred!into!
naïve!IFN.γ!knock.out!C57BL/6!mice.!C57BL/6!mice!were!genotyped!to!confirm!their!
IFN.γ! KO! status! as! described! in! Chapter! 2.2.12.! Again,! there! was! no! statistically!
significant!reduction!in!C.)trachomatis!vaginal!load!at!day!3,!6!or!10!post!challenge!in!
C57BL/6! for! any! of! the! serum! transfusion! groups! (Kruskal.Wallis! test! with! Dunn’s!
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The! intranasal! PPPP! regimen,! adjuvanted! with! MPLA,! was! the! only! regimen!
investigated!capable!of!inducing!MOMP.specific!vaginal!IgA.!To!assess!whether!these!
MOMP.specific! vaginal! IgA! antibodies! could! confer! a! protective! role,! mice!
immunised! with! the! intranasal! PPPP! regimen! adjuvanted! with! MPLA,! were!
subsequently!challenged!vaginally!with!C.)trachomatis.!!
The!intranasal!PPPP!regimen,!adjuvanted!with!MPLA,!did!not!significantly!reduce!the!
Chlamydial! bacterial! load! at! 3,! 7,! 10! or! 14! days! post! challenge! below! that! of!
unvaccinated! control! BALB/c! mice! (Figure! 5.12).! As! a! control,! four! intranasal!




vaginal! IgA!concentrations,!and! the!absence!of!protection!suggests!a! lack!of!a! role!





















Figure! 5.12.! PPPP! +! MPLA! intranasal! immunisation’s! protective! ability! against! C.) trachomatis! in!
BALB/c!mice.!!
Six!weeks! after! the! final! vaccination!and!1!week!after!2mg! subcutaneous!Depo.Provera! treatment,!





PPPP + MPLA I.N. 































































Neither! the! intranasal! administration! of! the! AM! regimen,! nor! the! intravaginal!




protection! afforded! is! not! surprising.! If! there! were! any! significant! reduction! in!

























Figure! 5.13.! AM! regimen! by! intranasal! or! intravaginal! immunisation! and! it’s! protective! ability!
against!C.!trachomatis!in!BALB/c!mice.!!
Six! weeks! after! the! final! vaccination! and! 1! week! after! 2! mg/mouse! subcutaneous! Depo.Provera!
treatment,!BALB/c!mice!(n!=!10)!were!infected!intravaginally!with!4x105!IFU!of!C.trachomatis!D/UW.
3/Cx.!The!vaginal!vault!of!each!mouse!was!sampled!using!individual!swabs!at!3,!7,!10!and!14!days!post!
challenge,! and! vaginal! Chlamydial! loads! quantified! by! infection! assay! and! immunoflorescent!


































































We! employed! two! differing! mouse! strains! for! our! challenge! studies:! BALB/c! and!
B6C3F1! (female!C57BL/6!and!male!C3H/HeN!cross).!Genital! tract! infection!of!mice!
with!C.)trachomatis!has!been!previously!shown!to!be!dependent!on!the!mouse!strain!
used,!with!a!genital!C.) trachomatis! serovar!E! infection!having!a!significantly! longer!
duration! of! infection! in! C3H/HeN! mice! than! in! C57BL/6! [273].! Furthermore,! C.)
trachomatis! serovar!D!genital! infections! in!BALB/c!mice!are!of! significantly! shorter!
duration!than!infection!of!both!C57BL/6!and!CF.1![108].!We!observed!no!statistical!
differences! in! the!C.) trachomatis! serovar! D! chlamydial! loads! between! our! BALB/c!
and!B6C3F1!at!any!sampling!point!within!the!first!15!days!post!challenge,!but!there!
were!statistically!different!immune!responses!in!the!differing!mice!strains!to!certain!
regimens.! ! The!DAMP! regimen! induced! significantly! greater!MOMP.specific! serum!
IgG! concentrations! in! B6C3F1!mice! than! in! BALB/c!mice,! and! the! T! cell! responses!
induced!by! the!DAMP,!DDD,!AMPP! and!AM! regimens!were! significantly! greater! in!
B6C3F1! mice! than! in! BALB/c! mice.! The! DAMP! regimen! was! the! only! regimen! to!
significantly!reduce!C.)trachomatis!vaginal!shedding!in!both!BALB/c!and!B6C3F1!mice,!
and! this! protection! was! subsequently! lost! following! CD4+! T! cell! depletion.! There!
appears!to!be!a!lack!of!a!role!for!antibodies!in!the!protection!afforded!by!the!DAMP!




Our! DAMP! vaccination! regimen! resulted! in! a! median! reduction! in! genital! C.)
trachomatis)serovar!D!bacterial!load!by!~1!log10!in!B6C3F1!and!by!~2!log10!in!BALB/c!
at! day! three! post! infection.! Both! are! significant! reductions! compared! to!
unvaccinated! naïve! mice.! Previous! chlamydia! vaccine! studies! have! resulted! in!
differing! degrees! of! protection.! In! BALB/c!mice,! compared! to! the! AS01B! adjuvant!
alone,! there! were! 1! log10! reductions! in! genital! C.) trachomatis! serovar! K! bacterial!




with! ovalbumin! [148].! Pal! et) al.! investigated! the! protection! afforded! by! MOMP!
formulated!with!adjuvants!developed!for!human!vaccines.!!In!BALB/c!mice,!MOMP!+!
MF59!resulted!in!a!genital!bacterial!load!of!10!IFU!after!7!days,!however!the!OVA!+!
MF59! control! also! had! a! low! bacterial! load! of! only! 30! IFU.! Furthermore,! the!
percentage! shedding! between! the! two! groups! were! similar! with! 69%! to! 78%!
respectively! [279].! We! could! only! obtain! significant! reductions! in! chlamydial!
shedding!compared!to!unvaccinated!naïve!controls!at!day!3!post!challenge,!as!by!day!
7! the! unvaccinated! naïve! mice! appear! to! control! the! infection,! with! a! dramatic!
reduction!in!shedding!in!both!vaccinated!and!unvaccinated!BALB/c!and!B6C3F1!mice.!
The! use! of! Chlamydia) muridarum! as! the! challenge! species! may! have! provided! a!
longer! sampling! window! to! investigate! differences! in! shedding! loads! between!





AMPP.! The!DAMP! regimen!has! been! shown,! however,! to! afford! protection! that! is!
significantly! better! than! no! intervention! (the! unvaccinated! naïve! control! mice)! in!
both!BALB/c!and!B6C3F1!mouse!strains.!
!
We! decided! to! screen! the! protective! efficacy! of! our! vaccine! regimens! in! two!
different!mouse!strains:!BALB/c!and!the!cross!strain!B6C3F1.!These!are!two!currently!






strains.! Eight! weeks! following! the! intranasal! immunisations! the! mice! were!
challenged! in! the! genital! tract! and! all! three! strains! of! mice! were! significantly!
protected,! with! no! shedding! at! any! time! point! post! challenge! in! C3H/HeN! and!
C57BL/6,! but! with! low! bacterial! shedding! in! the! BALB/c! mice! [280].! These! subtle!
infection! differences! in! the! differing!mouse! strains! even! following! live! chlamydial!
immunisation! indicate! the! importance! of! screening! novel! vaccines! and! the!
vaccination!regimens!in!multiple!mouse!strains.!!
The! distinct! characteristic! of! the! DAMP! vaccination! regimen! was! the! significantly!
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high! IgG2a:IgG1! ratio! it! induced.! There! are! examples! of! chlamydial.specific! IgG2a!
antibody! concentrations! correlating! with! protection! in! animal! studies.! Anti.CPAF!
IgG2a! levels!were! significantly! elevated! in! both! the! serum! and! vaginal! fluids! after!
CPAF!+!IL.12!vaccination!in!comparison!to!animals!that!received!CPAF!alone,!and!it!
was!the!CPAF!+!IL.12!vaccinated!mice!which!displayed!significantly!reduced!bacterial!
shedding! upon! challenge! [151].! MOMP! with! Freund’s! adjuvant,! formulated! by!
vortexing,! elicited!higher! IgG2a! than! IgG1,!while! formulation!by! sonication!elicited!
the!reverse.! It!was! then!only! the!mice! immunised!with!vortexed!MOMP!that!were!
significantly! protected! against!C.)muridarum! challenge! in! terms!of! number!of! IFUs!
and!length!of!shedding!time,!compared!to!sonicated!MOMP!vaccinated!mice![148].!
Intramuscular! immunisation! with! recombinant! MIP! (macrophage! infectivity!
potentiator! –! an! immunodominant! C.) muridarum! antigen)! induced! more! antigen!
specific! IgG2a! than! IgG1!as!well! as!elevated! IFN.γ,! and! these! immunised!mice!had!
significantly! reduced! vaginal! bacterial! shedding! by! day! 12! after! intravaginal!
chlamydial! challenge! and! less! severe! hydrosalpinx! compared! to! GST.immunised!
controls! [281].! An! intramuscular! immunisation! with! a! C.) trachomatis! serovar! D!
MOMP! formulation! that! included! a! PorB! DNA! plasmid! and! a! Vibrio! cholera! ghost!
preparation!elicited!high!concentrations!of!IgG2a!and!IgA,!and!significantly!reduced!
vaginal! C.) trachomatis! shedding! both! in! terms! of! duration! and! intensity,! with!
complete! resolution! by! two! weeks! post! challenge! [282].! There! are! potential!
mechanisms!by!which!these!high!IgG2a!and!low!IgG1!chlamydial.specific!antibodies!
may! be! operating.! EB! opsonisation! by! IgG! isotypes! has! been! shown! to! affect! the!
uptake! of! chlamydia! into! cells.! The! coating! of! EBs!with! the!mouse! isotype! IgG2b,!
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resulted! in! the! increased! infection!of! cells! through! the! interaction!with! the!mouse!
FcγRII! [283].!More! recently,! EB! opsonisation!with! a! high! IgG1! and! low! IgG2a! anti.
MOMP! polyclonal! sera!was! shown! to! enhance! infection! of! a! cell! line! through! the!
FcRn! mediated! uptake! of! these! IgG.coated! EBs,! suggesting! a! negative! role! for!
MOMP.specific! IgG1! antibodies! [284].! ! The! IgG2a! isotype! can! mediate! effector!
functions! such! as! antibody.dependent! cellular! cytotoxicity! (ADCC)! through! it’s! Fc!
region! binding! to! FcγR! [285]! [286].! Specific! anti.chlamydial! antibodies! have!
previously!been!shown!to!augment!the!macrophage!killing!of!infected!epithelial!cells!
via! ADCC! suggesting! this! effector! function! may! facilitate! the! early! clearance! of! a!
chlamydial! infection! [287].! Collectively,! these! suggest! that! the! anti.MOMP! IgG!
isotype! may! have! a! causative! role! in! the! protection! observed! from! the! DAMP!
regimen,!though!this!would!need!to!be!investigated!further.!!
!
The! protection! afforded! by! the! DAMP! regimen! was! lost! when! CD4+! T! cells! were!
depleted! prior! to! genital! challenge,! revealing! the! protection! is! CD4.dependent.!
Previous!chlamydia!vaccine!investigations!have!also!revealed!a!role!for!CD4+!T!cells!
in! their! protection.! Olsen! et) al.,! showed! that! the! genital! protection! induced! by!
subcutaneous!immunisation!with!recombinant!CTH1!adjuvanted!with!CAF01!in!mice!
was!solely!CD4+!T!cell!mediated![105].!The!same!research!group!also!revealed!that!
the! genital! protection! provided! to! C57BL/6!mice! by! the! liposomal! delivery! of! a!C.!
muridarum!MOMP!antigen!was!dependent!on!CD4+!T! cells! and!not!dependent!on!







their! depletion! after! CPAF! +! IL.12! vaccination,! but! moreover,! anti.chlamydial!
immunity! could! be! adoptively! transferred! to! naïve! recipients! using! CPAF.specific!




Following! our! serum!passive! infusion! experiments,! in!which! the! transfer! of! DAMP!
serum! did! not! significantly! reduce! the! genital! bacterial! loads! compared! to! naïve!
serum! controls,! we! concluded! a! lack! of! a! role! for! antibody! below! the! transfused!
amount! of! 15! μg/ml! MOMP.specific! IgG.! Of! course,! serum! antibody! may! have! a!
significant! protective! effect! at! concentrations! higher! than! the! amount! we! could!
transfuse.! There!are,!however,! a! few!chlamydial! vaccine! studies!where! the! role!of!
antibody! is! debatable.! The! contribution! of! antibodies! to! the! vaccine.induced!




in! vaccination! with! CPAF! +! CpG,! and! there! was! in! fact! comparable! chlamydial!
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clearance! in! both!micromT! and!wild.type!mice! after! vaccination.! In! addition,! both!




equal! protection! yielded! by! the! native! and! recombinant!MOMP! antigens! suggests!




the! DAMP! protection.! The! role! of! neutralising! antibodies! in! previous! chlamydia!
vaccine!studies!is!chequered.!An!alum.adsorbed!MOMP.derived!oligopeptide!which!
when! immunised! subcutaneously! elicited! high! levels! of! anti.chlamydial! serum! IgG!
neutralising!antibodies!did!not!in!fact!protect!against!intravaginal!or!intrauterinal!C.)
trachomatis! serovar! D! challenge.! There! were! no! significant! differences! between!
immunised!or!control!mice!in!either!colonisation,!shedding,!or!duration!of!infection,!
leading! the!authors! to! suggest! the! serum!neutralising! antibodies! are! ineffective! in!
preventing! chlamydial! genital! tract! infection! [291].! In! another! study!native!MOMP!
proteins! were! stabilised! with! two! differing! detergents,! with! the! amphipol! A8.35!
providing! higher! neutralising! titres! (titre! =! 1250)! than! sera! from!mice! immunised!
with! nMOMP/Z3.14! (titre! =! 250).! The! nMOMP/A8.35! did! elicit! more! robust!
protection!against!C.)muridarum,!but!it!was!not!investigated!whether!it!was!due!to!
the!neutralising!ability!of! the! induced!antibodies.! The!authors!used!cell!depletions!
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and! demonstrated! that! protection!was! CD4+! but! not! CD8+! T! cell!mediated! [292].!
Novartis!Vaccines!expressed!the!chlamydia!antigen!HtrA!in!outer!membrane!vesicles!




However,!none!of! these!vaccinated!mice!were!challenged,! so! there! is!no!evidence!
that!these!neutralising!anti.HtrA!antibodies!are!protective!in)vivo![293].!!!!!!
Our! vaccine! regimen! involving! four! intranasal! protein! immunisations! adjuvanted!
with!MPLA!was!the!only!regimen!to!elicit!vaginal!MOMP.specific!IgA!antibodies,!yet!
this!group!was!still!not!statistically!protected!from!vaginal!C.)trachomatis!challenge.!!
In! Brunham! et! al.,! from! 95! women! naturally! infected! with! C.) trachomatis,! the!
secretory!IgA!specific!to!C.)trachomatis!in!cervical!secretions!demonstrated!a!striking!
inverse!correlation!with!recovery!of!the!bacteria!from!the!cervix,!suggesting!IgA!may!
regulate!chlamydial! shedding! in!humans! [294].!However,! the! resolution!of!primary!
and!secondary!C.)muridarum!genital!infections!in!IgA.deficient!(IgA./.)!mice!was!not!
different!from!that!in!IgA!+/+!mice.!Furthermore,!the!depletion!of!CD4+!T!cells!prior!
to! the! reinfection! of! IgA+/+! or! ./.! mice! had! limited! impact! on! immunity! to!
reinfection! indicating! that! IgA! antibodies! are! not! an! absolute! requirement! of! the!




control! and! reduce!bacterial! load! levels! for! 14!days!post! infection.! This! confirmed!
the! importance! of! IFN.γ! in) vivo! to! chlamydia! control! and! that! our! intravaginal! C.)
trachomatis! infection! procedure! is! correct! and! capable! of! establishing! a! vaginal!
infection.! The! importance! of! IFN.γ! in) vivo! to! chlamydia! control! has! been!
demonstrated! previously! in! IFN.γ! ./.! mice,! and! mice! treated! with! anti.IFN.γ!
antibodies![114]![296]![297].!The!indoleamine!2,3.dioxygenase!(IDO)!pathway!which!
converts!L.tryptophan!to!N.formylkynurenine,!and!thus!limits!tryptophan!availability,!
is! implicated! in! the! IFN.γ!mediated! inhibition! of! chlamydial! replication! [298].! The!
mechanism! of! IFN.γ! depleting! tryptophan! availability! is! supported! by! the!
observation!that!C.)trachomatis!trachoma!serovars!whose!growth!is!inhibited!by!IFN.
γ! lack! tryptophan! biosynthesis! genes! [299].! IFN.γ! mediated! iron! deprivation! has!
been!suggested!to!control!chlamydial!infections!in)vitro![300]![301]![302],!and!IFN.γ!
may! have! a! regulatory! role! through! its! ability! to! alter! the! Th1/Th2! balance,! or! by!
enhancing!the!expression!of!chemokines!or!adhesion!molecules![303]![304],!though!
the!relative!roles!of!these!mechanisms!remains!to!be!studied.!NK!cells!participate!in!




complementary! in!providing!protective! levels!of! this! cytokine! [306].!Our! IFN.γR! ./.!
mice!did!eventually!resolve!the!genital!chlamydial!infection,!suggesting!the!presence!
of!IFN.γ.independent!mechanisms!of!chlamydial!load!reduction.!!
In! this! chapter! we! aimed! to! assess! the! protective! capacity! of! MOMP.based!
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heterologous!prime.boost! regimens!against!vaginal!C.) trachomatis! infection! in! two!
differing!mouse!models!and!to!investigate!the!mechanism!of!the!vaccine!induced!C.)
trachomatis! protection.! The! major! finding! from! this! chapter! is! that! the! DAMP!
vaccination! regimen! significantly! reduced! the!C.) trachomatis! vaginal! load! at! day! 3!
post.infection! in! both! BALB/c! and! B6C3F1! mouse! strains.! This! vaccine.induced!
reduction! in! chlamydial! load!was! lost! following! the!depletion!of!CD4+!T! cells! from!
vaccinated! mice! indicating! the! protection! is! CD4+! mediated.! Protective! and! non.
protective! vaccination! regimens! yielded! similar! C.) trachomatis! EB! serum!
neutralisation! profiles! suggesting! a!minimal! role! for! neutralising! antibodies! in! this!
vaccine.induced! protection,! and! the! passive! transfer! of! DAMP! serum! into! naïve!
C57BL/6!mice!did!not!significantly!reduce!C.)trachomatis!shedding,!further!indicating!
a!lesser!role!for!antibodies!in!this!vaccine.induced!protection.!Antibodies!may!play!a!




























Trachoma! is!a! chronic! conjunctivitis! caused!by! the! infection!of!epithelial! cells!with!









five! clinical! grading’s.! Follicular! trachoma! (TF! grade)! is! mild! asymptomatic!
inflammation! with! immune! cells! visible! on! the! upper! tarsal! conjunctiva;! intense!
inflammatory!response!(TI!grade)!has!most!of!the!tarsal!plate!obscured!by!capillary!
congestion;! scaring! trachoma! grade! (TS)! is! the! scaring! of! the! conjunctiva! from!
repeated! ocular! infections;! trichiasis! grade! (TT)! is! the! distortion! of! the! eye.lids!
(entropion)!and!deviation!of!the!eyelashes!to!cause!abrasion!of!the!orb!of!the!eye,!




has!a! sustained!effect! in!preventing!an! individual! going!blind!but!has!no!effect!on!
trachoma! transmission,! while! prophylactic! antibiotics! reduce! the! transmission! of!
infection! but! unless! frequently! repeated! has! no! long.lasting! effect! on! disease!
eradication! [310].! Sustainable! reductions! in! transmission! are! likely! through!
environmental! improvement! and! improved! hygiene.! ! Having! said! this,! the! most!
effective! treatment! in! terms! of! practicality! and! cost! would! be! a! vaccine! against!
trachoma.!Empirical!attempts!in!the!1960s!and!1970s!to!vaccinate!with!crude!whole!
organism! vaccines! were! unsuccessful,! with! some! subjects! protected,! but! a!
suggestion! that! other! vaccinees! in! fact! developed! enhanced! disease! [311].! ! These!
adverse!hypersensitivity! responses!were!not! related!to!serovar,!and!they!persisted!





host! genotype! determined! differences! in! susceptibility! to! severe! scarring! disease!
[314].!!
Research! into! the! protective! immune! responses! required! against! trachoma! is!
currently!on!going,!using!both!nonhuman!primate!models!alongside!human!sampling.!
Kari! et! al.! recently! investigated! potential! contributing! factors! to! the! protracted!
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clearance!of!a!primary!C.)trachomatis!ocular!infection!in!nonhuman!primates![315].!








changing! from! culture! negative! to! culture! positive! periods! over! the! course! of! a!
primary!infection!and!was!accompanied!by!moderate!to!severe!clinical!disease.!Thus!
A2497! infection! of! NHPs! closely!mimics! trachoma! in! humans! and! the! authors! re.






diversity!of!antigenic! targets!extracted!under!non.denaturing!native! conditions,! an!
important!difference!from!Western!blotting!which!usually!involves!denatured,!non.
native! antigen! conformations.! Antibody! recognition! from! the! NHP! sera! was!
restricted! to! the! antigenically! variable! MOMP! and! a! few! antigenically! conserved!
antigens.! Recognition! of! MOMP! occurred! early! (2.4! weeks)! post.infection,! and!
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correlated!with! the! reduction! in! infectious! ocular! burdens,! but! not! with! infection!
eradication.! However,! antibody! recognition! against! the! conserved! antigens! PmpD,!
Hsp60,!CPAF!and!Pgp3!appeared!late!(9.14!weeks!post!infection)!and!correlated!with!
infection!eradication.!!
Though! in! the! previous! chapter! we! revealed! CD4+! T! cells! to! be! important! in!
conferring! protection! against! the! vaginal! infection! with! C.) trachomatis,! with! a!
minimal!role!(if!any)!for!antibodies,!it!is!entirely!feasible!for!a!differing!mechanism!to!
be! at! play! in! the! ocular! environment.! Ocular! strains! of! C.) trachomatis! lack!
tryptophan!synthase!function,!a!function!thought!to!have!arisen!or!maintained!due!
to! IFN.γ! pressure,! suggesting! a! lack! of! a! sole! role! for! IFN.γ! in! the! clearance! of!
trachoma![316].!Any!role!for!IFN.γ!dependent!Th1!cells!in!human!ocular!infection!has!
yet! to! be! confirmed! and! the! importance! of! humoral! immunity! to! trachoma! is!
currently!unclear![317].!!!!
MOMP! has! already! been! extensively! discussed! within! this! thesis.! PmpD! is! a!
polymorphic!outer!membrane!protein! found!on! the! surface!of! chlamydial! EBs! and!
has! previously! been! shown! to! generate! neutralising! antibodies! [205].! It! is! highly!
conserved! and! involved! in! the! chlamydial! attachment! to! host! cells! [318].! Pgp3! is!
transcribed! and! expressed! from! a! highly! conserved! gene! contained! within! an!
episomal!cryptic!plasmid!of!C.)trachomatis!and!is!secreted!into!the!inclusion!lumen!
and! the! host! cell! cytosol.! Purified! Pgp3! can! stimulate! macrophages! to! release!
inflammatory!cytokines!suggesting!a!role!in!chlamydial!pathogenesis![319].!!
In! this! chapter! we! aim! to! assess! whether! heterologous! prime.boost! vaccine!
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regimens! utilising! the! third! generation! vaccines! constructed! within! this! thesis! are!
capable! of! inducing! Chlamydial! specific! antibody! responses! on! the! murine! ocular!
mucosa.!As!trachoma!is!an!ocular!disease!and!the!MOMP.,!PmpD.,!and!Pgp3.specific!
antibodies! correlated! with! reduction! and! eradication,! we! wanted! to! investigate!
whether!a!vaccination!regimen!could!induce!antibodies!specific!to!these!potentially!
important!chlamydial!antigens!on!the!murine!eye.!We!screened!a!set!of!prime.boost!
regimens! using! DNA,! HuAd5,! MVA! and! recombinant! protein! vaccines! expressing!
MOMP! to! test!which!were! capable!of! inducing! the!highest! concentrations!of! anti.
MOMP! antibodies! on! the! murine! eye.! This! regimen! was! then! used! with! the!
additional! recombinant!protein!antigens!PmpD!and!Pgp3!to! investigate!whether!as!









• To! screen! a! set! of! prime.boost! regimens! using! DNA,! HuAd5,! MVA! and!





















6.2.1 Intramuscular! heterologous! primeWboost! regimens! induce! MOMPW
specific!ocular!IgG!responses!
The! C.) trachomatis! antigen! MOMP! was! assessed! in! BALB/c! mice! immunised! in!
heterologous!prime.boost! regimens!with!DNA,!HuAd5,!MVA!and!protein! (+!MF59)!
based!vaccines.!Immunisations!were!administered!three!weeks!apart!and!the!ocular!
mucosa! sampled! two! weeks! post.final! immunisation! (Figure! 6.1A).! The! ocular!
mucosa!sampling! is!described!in!detail! in!Chapter!2.4.12.! !PPP!induced!significantly!
higher!MOMP.specific!ocular!IgG!concentrations!than!DDPP!(**!p!≤!0.005)!and!naïve!




Total! IgG! concentrations! of! the! ocular! samples! were! measured! by! ELISA! and! the!
MOMP.specific! ocular! IgG! concentrations! were! normalised! to! 1! μg! total! IgG!
revealing!the!proportion!of!total!ocular! IgG!which! is!specific!to!the!antigen! in!each!
heterologous! prime.boost! vaccination! regimens! (Figure! 6.1B).! The! PPP! regimen!
induced!MOMP.specific!ocular! IgG!antibodies!that!accounted!for!more!than!half!of!
the! total! IgG!on! the!ocular!mucosa! (mean!=!511!ng! specific/μg! total).! ! The!AMPP,!
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Three! selected! chlamydial! antigens,!MOMP,! PmpD,! and! Pgp3,!were! used! in! three!
protein! immunisations! adjuvanted!with!MF59.!Hsp60!was!not! chosen!as! a! vaccine!
antigen! due! to! its! potential! immunopathogenic! effect.! Exposure! to! the! chlamydial!
hsp60! is! thought! to! generate! an! immune! response! that! also! recognises! regions!of!
human! hsp60! due! to! their! close! homology! and! this! production! of! cross.reactive!
antibodies! and! cell.mediated! immunity! to! human! hsp60! is! implicated! in! increase!
susceptibility!to!atherosclerosis!and!autoimmune!disorders![320].!With!MOMP!being!
implicated! in! the! chlamydial! load! reduction! and!PmpD!and!Pgp3! implicated! in! the!
chlamydial!eradication,!the!antigens!were!thus!investigated!in!cocktail!formulations!
as! they!would! likely! be! in! an! actual! vaccine! formulation.!Mice!were! vaccinated! in!
groups!(n!=!8)!with!individual!or!combinations!of!recombinant!proteins;!PmpD!alone,!
Pgp3!alone,!MOMP!+!Pgp3!cocktail,!and!MOMP!+!Pgp3!+!PmpD!cocktail!(Figure!6.2A).!
PmpD,! whether! administered! alone,! or! in! combination,! consistently! had! lower!
PmpD.specific!ocular!IgG!concentrations!(PmpD!alone,!mean!=!7.5!ng/ml;!PmpD!with!
MOMP! and! Pgp3,! mean! =! 1.06! ng/ml)! than! MOMP.! or! Pgp3.specific! ocular! IgG!
concentrations.! Pgp3.specific! ocular! IgG! concentrations! were! consistent! whether!
immunised!with!Pgp3!alone!(mean!=!24.2!ng/ml)!or!immunised!in!combination!with!
MOMP!(mean!=!18.4!ng/ml)!or!with!MOMP!and!PmpD!(mean!=!14.2!ng/ml).!!MOMP.






















































































































specific! ocular! IgG! concentrations.! There! were! significantly! higher! MOMP.specific!
ocular! IgG! concentrations! (***! p! ≤! 0.0005)! and! significantly! higher! Pgp3.specific!
ocular! IgG! concentrations! (**! p! ≤! 0.005)! than! PmpD.specific! ocular! IgG! (one.way!
ANOVA!with! Bonferroni’s! multiple! comparison! post.test).! There! was! no! statistical!
difference! between! the! antigen.specific! ocular! IgG! concentrations! in! the!MOMP!+!
Pgp3!vaccine!cocktail.!!!!!!




concentrations! were! compared! against! the! antigen.specific! serum! IgG!
concentrations! for! all! the! antigens! (Figure! 6.3).! A! significant! correlation! was!
observed!between! the! antigen.specific! serum! IgG! concentrations! and! the! antigen.
specific!ocular!IgG!concentrations!(*!p!=!0.0131)!with!a!Pearson!R!squared!of!0.1107.!
































































6.2.3 PPP! regimen! does! not! induce! chlamydialWspecific! ocular! IgA!
antibodies!
The! chlamydial! antigens! MOMP,! Pgp3,! and! PmpD! did! not! induce! antigen.specific!
ocular! IgA! antibodies! in! detectable! concentrations! (Figure! 6.4).! This! is! interesting!
because!there! is!a!high!concentration!of!total! IgA!on!the!ocular!mucosa!as!evident!
from!total!IgA!ELISAs!on!the!ocular!samples,!with!naïve!unvaccinated!BALB/c!ocular!
samples! having! a! mean! total! IgA! concentration! of! 494! ng/ml.! The! mean!
concentration!of!total!IgA!differed!following!the!heterologous!prime.boost!regimens,!
though!not!significantly!from!the!naïve.!The!PPP!regimen!had!mean!total!ocular!IgA!
concentrations! of! 1.01! μg/ml,! and! the! DAMP! regimen! of! 0.98! μg/ml.! This! is! in!
comparison! to! total! IgG! concentrations! of!mean! 67! ng/ml! for! PPP! and! 127! ng/ml!
total! IgG! for! DAMP.! The! proportions! of! IgG! to! IgA! differ! on! the! ocular! surface! in!
comparison!to!the!serum!suggesting!that! if!a!vaccination!regimen!could! induce!IgA!
antibodies,! the! active! transport! of! IgA! should! allow! for! appreciable! and! perhaps!
effective!antigen.specific!IgA!on!the!murine!ocular!mucosa.!Either!the!three!antigens!
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6.2.4 Pgp3,! PmpD! and!MOMP! protein! vaccine! cocktails! in! a! PPP! regimen!
are!not!protective!against!vaginal!C.)trachomatis!challenge!
The!mouse!model!for!trachoma!is!rarely!used,!with!the!establishment!of!a!chlamydia!
infection! technically! difficult! on! the! small! size! of! the! mouse! eye.! Therefore,! as! a!
potential!correlate,! the! immunised!BALB/c!mice!were! infected!vaginally!with!4x105!
IFU!of!C.) trachomatis!D/UW.3/Cx!as! in!previous!challenge!experiments! throughout!
this! work.! None! of! the! vaccines! (PmpD,! Pgp3,! MOMP+Pgp3,! nor!
MOMP+Pgp3+PmpD)! in! the! PPP! regimen! (adjuvanted! with! MF59)! significantly!
reduced! chlamydial! loads! compared! to! unvaccinated! controls! (Figure! 6.5).! Though!
different!antigens,!this!data!corroborates!with!the!lack!of!protection!seen!for!MOMP!
alone!+!MF59! in!the!PPP!regimen! in!BALB/c! (chapter!5.2.6).! It!would!have!been!of!
interest!to!investigate!the!partially!protective!DAMP!regimen!utilising!the!additional!
antigens! PmpD! and! Pgp3,! to! assess! whether! the! chlamydial! load! reduction! was!
greater! and! the! chlamydial! clearance! was! quicker! with! respect! to! MOMP! alone.!





















Six! weeks! after! the! final! vaccination! and! 1! week! after! 2! mg/mouse! subcutaneous! Depo.Provera!
treatment,!BALB/c!mice!(n!=!8)!were!infected!intravaginally!with!4x105!IFU!of!C.)trachomatis!D/UW.
3/Cx.!The!vaginal!vault!of!each!mouse!was!sampled!using!individual!swabs!at!3,!7,!and!10!days!post!
challenge,! and! vaginal! Chlamydial! loads! quantified! by! infection! assay! and! immunoflorescent!

































































































































murine! eye! following! vaccination! is! unique.! From! literature! searches,! ocular!
antibodies! are! normally! sampled! from! non.human! primates! (NHPs)! [321]! [322]! or!
humans![323]![324].!!
!
Kari! et) al.! showed! that! specific! serum! antibody! signatures! correlated! with! ocular!
infection! reduction! and! differing! signatures! correlated! with! ocular! infection!
eradication!in!macaques![315].!If!the!antigen.specific!antibodies!have!in!fact!a!direct!
mechanistic!role,!we!have!developed!an!optimal!vaccination!regimen!to!induce!them!
on! the!murine!eye! allowing! the! future!prospect!of! screening! the! specific! antibody!
induction!potential!of!new!chlamydia!vaccine!antigens.!Our!data!demonstrated!that!
not!all!antigens!are!capable!of!inducing!equal!concentrations!of!antigen.specific!IgG,!
with! for! example! the! PmpD! inducing! significantly! less! than! either! Pgp3! or!MOMP!
antigens.!This!may!be!because!PmpD! is!a! less! immunogenic!antigen,!or!due!to! the!
slight!dose!difference!during!vaccinations.!Our!model!for!the!induction!of!chlamydial!
specific! antibodies! also! lends! itself! to! the! screening! of! antigens! that! may! induce!
neutralising! antibodies,! with! the! antibodies! sampled! from! the! eye! being! used! in!




The! chlamydial.specific! ocular! IgG! concentrations! significantly! correlated! with! the!
chlamydial.specific! serum! IgG! concentrations! (Figure! 6.3),! strongly! suggesting! that!
the! antibodies! detected! on! the! ocular!mucosa! are! serum! exudate.! It!would! be! of!
interest!in!future!studies!to!investigate!whether!this!holds!true!outside!of!the!mouse!
model.! Other! experimental! data! have! shown! that! establishing! a! high.level! serum!
response! can!protect!mucosally! through! the! antibody!exudation!mechanism.!HPV.
specific! neutralising! serum! antibodies! that! are! important! for! reliable! protection!
against! HPV! infection! are! able! to! transudate! or! exudate! from! the! serum! to! the!
cervical! mucosa! and! may! protect! against! new! HPV! infection,! prevent! a! current!




whether! other! adjuvants! used! in! the! PPP! regimen! could! elicit! equally! high! IgG!
concentrations! but! of! differing! isotypes,! as! MF59! skews! the! IgG! type! to! IgG1!
predominance! [329]! [330].!With! the! same! antigen,! differing! adjuvants! have! been!
shown! to! influence! the! antibody! isotype! in!mice.! The! IgG3! isotype!was! produced!
mainly! after! immunisation! with! lipopolysaccharide! (LPS)! or! Lithium! salt,! IgG1!was!
produced! with! incomplete! Freund's! adjuvant! (IFA),! complete! Freund's! adjuvant!
(CFA),!alum!and!poly!I:C.!Poly!A:U!favoured!the!production!of!IgG2b,!and!CFA,!alum!





There! was! a! high! concentration! of! measurable! total! IgA! on! the! murine! ocular!
mucosa,! however! neither! MOMP,! PmpD,! nor! Pgp3! by! the! PPP! +! MF59! regimen!
induced! any! specific! IgA.! This! maybe! an! antigen! issue,! or! an! effect! of! the!
adjuvantation! or! due! to! the! intramuscular! route! of! immunisation.! Concerning!
adjuvantation,! the! TLR.independent! molecule! Cholera! Toxin! subunit! B! (CTB)! is!
widely!used!as!a!mucosal!adjuvant!to!induce!IgA![333]![334],!with!CTB!enhanced!IgA!
responses! against! inhaled! allergens! in! the! mouse! model! [335].! The! route! of!
immunisation! has! been! shown! to! alter! IgA! induction,! with! the! intranasal!
immunisation!of!the!influenza!X:31!antigen!inducing!significantly!higher!IgA!titres!in!
all!mucosal!secretions!(lungs,!nasal!and!vaginal)!compared!to!the!subcutaneous,!oral!
and! intrarectal! routes! [336].! Moreover,! oral! administration! of! a! GBS! type! III! CPS!
conjugated! vaccine! with! the! recombinant! cholera! toxin! B! subunit! induced! high!
specific! IgA! levels! in! the! lungs!and! rectum!of!mice! [337].! In!Chapter!4!we! showed!
that! four! intranasal!MOMP! immunisations! adjuvanted!with!MPLA!were! capable!of!
inducing!MOMP.specific!IgA!in!the!vaginal!washes,!yet!the!IgA!concentrations!were!
low! suggesting! there! may! be! issues! in! inducing! sizable! MOMP.specific! IgA!
concentrations!with!this!antigen!or!adjuvant!combination.!!!!!
!





of! disease.free! individuals! was! in! fact! associated! with! an! increased! incidence! of!




antibodies! are! raised! against,! as! isotype! differences! and! antigen.specificities! have!
shown!differential!uptake!and!translocation!of!chlamydia!into!cells!in)vitro![284].!
!
There! is! a!murine!model! of! ocular! infection! by! a! human!biovar! of!C.) trachomatis.!
Unfortunately! this! could!not!be!explored!within! the! scope!of! this!work!due! to! the!
serovar! specificity! of! the! MOMP! sequences! in! our! vaccines,! due! to! the! lack! of!
availability! of! high! titre! C.) trachomatis! ocular! serovar! stocks,! due! to! our! serovar!
specific!chlamydia!detection!reagents,!and!due!to!the!local!animal!facility!guidelines.!
However,! future!work!would! be! to! assess! the! different! antigens! in! varying! prime.
boost! regimens!within! this!murine!model!of!ocular! infection.!The!murine!model!of!
ocular! infection! has! been! established! in! BALB/c! and! C3H/HeN!mice! involving! the!
topical!infection!of!the!conjunctiva!with!C.)trachomatis!serovar!C!at!a!dose!of!5000!
IFU.!The!conjunctival!surfaces!of!both!eyes!are!then!swabbed!with!Dacron!urethral!







We! carried! out! vaginal! chlamydial! challenges! as! a! surrogate,! to! investigate! any!
protective! efficacy! of! the! three! antigens,! either! individually! or! in! combination.!
However! none! of! the! vaccinated! groups! significantly! reduced! chlamydial! shedding!
below!that!of!unvaccinated!naïves.!Potentially! relevant! to!PmpD!and!MOMP! is! the!
likely! requirement! to! induce! humoral! immunity! to! conformationally! dependent!
epitopes,! such! as! epitopes! capable! of! inducing! neutralising! antibodies.! This! is!
supported!by! the! findings! that!native!MOMP! is!a! superior! immunogen! for!eliciting!
protective!immunity!in!both!the!mouse!and!NHP![163]![341].!More!recently!Lu!et)al.!
used! GST.tagged! antigens! expressed! in! a! heterologous! system! and! described! the!
recognition! of! multiple! potentially! important! chlamydial! proteins! in! trachoma!
patients.!However,!their!experiments!failed!to!recognise!PmpD!and!MOMP,!the!two!
most! immunogenic! proteins! of! Chlamydia,! likely! because! recognition! of! these!
antigens! in! humans! is! dependent! on! native! confirmation! [342].! Another! potential!
reason!why! none! of! the! antigens! (either! individually! or! in! combination)! conferred!
protection! may! be! due! to! the! swift! clearance! of! chlamydia! in! our! mouse! model.!
From!the!Kari!et)al.!paper,! the!antibodies!specific! for!MOMP!appeared!to! function!
early! in! infection! thus! reducing! early! chlamydial! burdens,! whereas! antibodies!
specific! to! Pgp3! and! PmpD! appeared! later! and!were! suggested! to! be! required! to!
eradicate!infection!at!later!time!points![315].!In!a!separate!study,!the!use!of!Pgp3!as!
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an! immunogen! in!BALB/c!mice! revealed!protection!against!C.)muridarum!was!only!
limited! to! later! time!points! [343].!An! issue!with! the!murine! genital!C.) trachomatis!
challenge!model! is! that! the!mice!do!not! have! long! enough!periods! of! infection! to!
assess! the! role!of! late!acting!antibodies.!Due! to! the!clearance!of!C.) trachomatis! in!
naïve! mice,! there! are! only! three! days! post! challenge! where! one! can! confidently!
observe! any! significant! chlamydial! load! reduction! via! vaccination.! The! use! of! C.)
muridarum!may!avoid!this!issue.!A!final!reason!for!the!lack!of!significant!protection!
afforded!by!the!antigens!and!a!major!caveat!of!the!research!from!Kari!et)al.,!is!that!
one! cannot! conclude! that! antibodies! are! the! primary! protective! mechanism.! The!
antibody! signatures! observed! in! the! NHPs! may! simply! be! surrogate! markers! of!
protective! T! cell! immune! responses.! However,! if! antibodies! (whether! neutralising,!
opsonising,! ADCC)! do! prove! to! be! of! protective! importance! from! future! trachoma!
research,! we! have! developed! a! model! for! the! sampling! and! analysis! of! ocular!
antibodies! and! have! revealed! the! vaccination! regimen! required! to! induce!
significantly!greater!concentrations!on!the!ocular!mucosa.!!!!!!
This! chapter! aimed! to! assess!whether! heterologous! prime.boost! vaccine! regimens!
utilising! the! third! generation! vaccines! constructed! in! this! thesis! were! capable! of!
inducing! Chlamydial! specific! antibody! responses! on! the!murine! ocular!mucosa.! All!
the!heterologous!prime.boost!vaccine!regimens!tested!using!the!DNA,!HuAd5,!MVA!
and! recombinant!MOMP! based! vaccines!were! capable! of! inducing!MOMP.specific!
IgG! antibodies! on! the! murine! ocular! mucosa,! however! the! PPP! regimen! induced!
significantly! greater! anti.MOMP! ocular! antibody! concentrations.! This! regimen!was!
employed! with! the! additional! chlamydial! antigens! PmpD! and! Pgp3,! of! which! all!
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[344].! It! is! the!most! prevalent! sexually! transmitted! bacterial! infection;! indeed! the!
highest!clinically!reported!bacterial!infection!in!the!United!States!and!in!many!other!
developed!countries! [345]. Chlamydia! is!as! important! in!developing!countries!with!
the!WHO!estimating! that! 92!million! sexually! transmitted! infections! occur! annually!
and! the!majority! of! infections! occur! in! the!most! impoverished! areas! of! the!world!
where!control!programs!are!effectively!absent! [94].!Due! to!untreated! infections! in!
women!that!result!in!long.term!reproductive!problems!such!as!infertility!and!ectopic!






reported! case! counts! have! not! exhibited! sustained! declines! [347].! In! 2000,! in! the!
United! States!nearly! 710,000! cases!of!Chlamydia!were! reported,! rising! to!over!1.2!
million! reported! infections! in! 2009,! and! 2.8! million! infections! estimated! to! have!




significantly! increasing! at! ~5%! per! year! in! particular! among! young! women! [348].!
Brunham! &! Rappuoli! (2013)! propose! that! due! to! these! important! public! health!
issues,!an!accelerated!C.)trachomatis!vaccine!effort!is!required!with!a!C.)trachomatis!
vaccine!as!a!global!public!health!priority![344].!!
The! significance! of! this! work! and! a!major! accomplishment! of! this! research! is! the!
discovery!of!a!protective!vaccination!regimen,!which!furthermore!was!protective!in!
two! mouse! models! that! had! differing! immune! bias! potentials.! The! vaccination!
regimen!was! protective! in! that! it! significantly! reduced! the! vaginal! chlamydial! load!
compared! to! unvaccinated! controls! and! though! not! sterilising! in! its! protection,! a!
protective!regimen!nonetheless.!It!is!important!to!note!that!the!DAMP!regimen!was!
not! compared! against! the!other! investigated! regimens!directly,! so! it! has! not! been!
proven! to! be! superior! to! say! PPP! or! AMPP.! The! DAMP! regimen! has! been! shown,!
however,! to! afford!protection! that! is! significantly! better! than!no! intervention! (the!
unvaccinated! naïve! control!mice)! in! both! BALB/c! and!B6C3F1!mouse! strains.! ! This!
DAMP!regimen!has!a!distinct!characteristic!and!thus!provides!a!potential!correlate!of!
protection!–! the!significantly!greater! IgG2a:IgG1!ratio! than!any!of! the!other! tested!
regimens.!This!IgG2a:IgG1!ratio!is!unlikely!a!mechanistic!correlate,!but!a!surrogate!of!
a! good! CD4+! T! cell! response.! The! transcription! factor! T.bet! directly! regulates! Th1!





This! is! the! first! use! of! DNA,! HuAd5,! MVA! and! recombinant! protein! in! sequential!
immunisations!against!Chlamydia,!and!the! first!ever!use!of! the!MVA!viral!vector! in!
chlamydia!vaccine!research.!Another!first! is!the!use!of!a!bioinformatically!designed!
MOMP!antigen!to!encompass!the!variability!of!C.)trachomatis!serovars!D!and!E,!and!
which! has! been! shown! here! to! provide! protection! against! a! challenge! with! C.)
trachomatis!serovar!D/UW.3/Cx.!!! 
A! vaccine! conferring! even! partial! protection,! such! as! this! DAMP! regimen! in! the!
mouse! models,! may! still! have! significant! population! effects! if! it! confers! partial!
protection!in!humans.!!Gray!et)al.,!mathematically!modeled!the!impact!of!potential!
vaccines! on! the! epidemics! of! C.) trachomatis,! and! showed! that! a! fully! protective!
vaccine!could!eradicate!epidemics!of!chlamydia!infection!within!20!years.!If!lifelong!
sterilising! immunity! cannot!be!attained,! then! their!models! reveal! that!a! chlamydia!
vaccine! would! need! to! be! effective! for! at! least! 10! years! for! population.level!
eradication! to! take! place.! However,! partially! protective! vaccines! could! still! be!
beneficial!at!the!population.level!as!long!as!they!increased!the!infectious!threshold!
required! for! transmission! to!~1.2! log10! from!the!peak! load.!Similarly,! vaccines! that!
reduce! the! peak! load! or! the! duration! of! infection! in! infected! individuals! can! have!
substantial! population.level! effects! [350].! As! it! is! still! unknown! what! the!




Chlamydia! vaccination.! Plasmid.free,! attenuated! strains! of! Chlamydia! have! shown!
promising!results!in!both!mouse!and!NHP!models.!A!plasmid.free,!attenuated!strain!
of! C.) muridarum) was! revealed! to! be! attenuated! during! murine! genital! tract!
infections! and! thus! not! result! in! upper! genital! tract! disease! [351].! This! plasmid.
deficient!strain!also!functioned!as!a!live!attenuated!vaccine!in!mice,!with!vaccination!
with! the! plasmid.deficient! strain! protecting! against! oviduct! disease! following!
subsequent! genital! infections! [352].! A! plasmid.deficient! C.) trachomatis! strain! has!
also!been! recently!utilised! in! the!macaque!model! to! investigate!protection!against!
virulent!ocular!C.)trachomatis!challenge.!This!vaccine!delivered!ocularly!elicited!solid!
and!partial!protective! immunity! in!macaques![353],!with!mechanistic! investigations!
later! revealing! an! important! and! unexpected! role! for! CD8+! T! cells! in! the! solid!
protection!observed![354].!!Plasmid.deficient!Chlamydial!strains!are!another!vaccine!
approach! to! induce! both! B! and! T! cell! responses,! but! with! the! added! potential! of!










An! initial! aim!of! this! thesis!was! to!computationally!assess!whether! the!amino!acid!
variability! within! the! Chlamydial! antigen! MOMP! could! be! encompassed! within! a!
consensus!or!a!mosaic!based!vaccine.!We!bioinformatically!attempted!to!encompass!
the! variability! of! the! chlamydial! antigen! MOMP,! with! the! consensus! approach!
providing!greater!epitope!coverage!and!native!structure!than!a!mosaic!antigen,!and!
DNA,! HuAd5! and!MVA! based! vaccines! were! successfully! constructed! expressing! a!
consensus!MOMP.!A! recombinant!consensus!MOMP!was!poorly!expressed! from!E.)
coli,!so!a!closely!related!MOMP!serovar!D!antigen!was!adopted!as!the!recombinant!
protein.! This! toolbox! of! MOMP.based! vaccines! allowed! us! to! investigate! which!
vaccine.induced!immune!responses!may!be!protective!against!C.)trachomatis!genital!
infections!in!the!murine!model.!!!!!!!!
We! subsequently! set! out! to! comparatively! assess! the! induction! of! humoral! and!
cellular! immunity! against! the! MOMP! antigen! following! heterologous! prime.boost!
vaccinations!with!the!newly!constructed!DNA,!HuAd5,!MVA!and!recombinant!protein!
based! vaccines.! This! revealed! a! capability! to! induce! an! array! of! MOMP.specific!
immune!responses,!both!cellular!and!humoral,!using!the!four!differing!MOMP.based!
vaccines! in! heterologous! prime.boost! regimens.! Protein! boosting! significantly!
increased! both! serum! and! vaginal! antibody! concentrations,! while! DNA! and! viral!
vector!alone!regimens!induced!the!greatest!cellular!responses!as!analysed!by!IFN.γ!
ELISpot.! Protein! boosts! increased! the! avidity! of! the! induced! specific.serum!
antibodies,!while!CD4+!T!cell!polyfunctionality!was!broadest!following!regimens!with!
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DNA! or! HuAd5! prime.! Regimens! were! grouped! on! the! distinct! MOMP.specific!
immune!environments! they!elicited,!and!taken!through! into!C.) trachomatis! vaginal!
challenge!studies!to!shed! light!on!the!relative!contribution!of!each!environment!to!
protective!immunity.!
We! then! aimed! to! assess! the! protective! capacity! of! these! MOMP.based!
heterologous!prime.boost! regimens!against!vaginal!C.) trachomatis! infection! in! two!
differing!mouse!models!and!to!investigate!the!mechanism!of!the!vaccine!induced!C.)
trachomatis!protection.!The!major! finding!was! that! the!DAMP!vaccination!regimen!
significantly!reduced!the!C.)trachomatis!vaginal!load!at!day!3!post.infection!in!both!
BALB/c!and!B6C3F1!mouse!strains.!This!vaccine.induced!reduction!in!chlamydial!load!
was! lost! following! the! depletion! of! CD4+! T! cells! from! vaccinated! mice! indicating!
CD4+! mediated! protection.! Protective! and! non.protective! vaccination! regimens!
yielded!similar!C.)trachomatis!EB!serum!neutralisation!profiles!suggesting!a!minimal!
role! for! neutralising! antibodies! in! this! vaccine.induced!protection,! and! the!passive!
transfer! of! DAMP! serum! into! naïve! C57BL/6! mice! did! not! significantly! reduce! C.)
trachomatis!shedding,!further! indicating!a! lesser!role!for!antibodies! in!this!vaccine.
induced!protection.!!
!The!final!aim!of!this!thesis!was!to!assess!whether!heterologous!prime.boost!vaccine!
regimens! utilising! the! third! generation! vaccines! constructed! in! this! thesis! were!





sought! to! investigate! whether! such! antibodies! could! be! induced! ocularly.! All! the!
heterologous!prime.boost!vaccine!regimens!tested!using!the!DNA,!HuAd5,!MVA!and!
recombinant!MOMP! based! vaccines! were! capable! of! inducing!MOMP.specific! IgG!
antibodies! on! the! murine! ocular! mucosa,! however! the! PPP! regimen! induced!
significantly! greater! anti.MOMP! ocular! antibody! concentrations.! This! regimen!was!
therefore!employed!with!the!additional!chlamydial!antigens!PmpD!and!Pgp3,!and!all!
antigens! induced!antigen.specific!ocular! IgG!antibodies.!We!believe! this! is! the! first!
study! to! have! evaluated! the! effects! of! vaccination! on! the! induction! of! chlamydial!




One!criticism!of! the!protective!DAMP!regimen! is! the! requirement!of! four! separate!
immunisations.! It! is! not! unusual! to! have! three! immunisations! in! a! vaccination!
regimen,! yet! the! addition! of! another! intervention! significantly! increases! the! costs!
and! reduces! patient! adherence.! A! potential! way! to! circumvent! this! issue! is! the!
option!of!mixed!vector!immunisation.!Reyes.Sandoval!et)al.,!have!recently!revealed!
that! the! administration! of! mixed! HuAd5! and!MVA! delivered! as! part! of! the! same!
formulation! in! fact! elicited! optimal! immunogenicity! and! conferred! protection! to!
mice!against!a!Plasmodium!challenge.!This!vector!mixture!was!dose!dependent!with!
higher! doses! of! vector! having! detrimental! effects! on! immunogenicity! [219].! This!
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mixed! vector! immunisation! could! be! tested! with! our! MOMP.based! vectors! to!
establish!whether! it! can! still! elicit! such! IgG2a:IgG1! ratios! for! this! antigen,! and! is! a!
potential!avenue!for!future!work.!!!!!!!!!!
There!are!other!potential!vaccine!delivery!platforms!that!warrant!investigation!in!C.)
trachomatis! vaccine! research.! Vaccine! antigens! expressed! in! attenuated! strains! of!
Salmonella)enterica!(Vaxonella®)!have!been!proven!safe!in!clinical!trials.!The!bacteria!
is! ingested,!passes! through! the! stomach!and! then! traverses! the! lining!of! the! small!
intestine! via!M! cells! into! lymphatic! nodules.! Here! they! are! phagocytosed! by! APCs!
such!as!macrophages!and!express!the!antigen!genes!to!stimulate!both!humoral!and!
cellular! immune! responses! [356].! Salmonella! is! an! intracellular! Gram.negative!
bacteria!like!Chlamydia,!so!the!presentation!of!antigens!in!this!similar!way!may!be!of!




Salmonella,! Pseudomonas,! Vibrio! and! E.) coli! have! all! induced! potent! protective!
immune! responses! against! the! pathogens! they! are! derived! from! [358]! [359]! [360]!
[361],! and! anti.Neisseria) OMV.based! vaccines! are! already! licensed! [362].! The!
protection!may! not! be! provided! only! by! the! presence! of! conformationally! correct!
immunogenic!antigens!but!also! that!OMVs!carry!many!PAMPs!which!play!a! role! in!
stimulating!innate!immunity!and!promoting!adaptive!immune!responses![363]![364]!





The! antibody! responses! elicited! by! our! vaccines! were! poorly! neutralising.! If!
neutralising!antibodies!were! found! to!have!a!positive!mechanistic! role! in! reducing!
chlamydial! loads,!approaches!to! induce!such!neutralising!antibodies!would!need!to!
be! explored.! The! neutralising! epitopes! of! MOMP! or! other! chlamydial! surface!
exposed!proteins!would!need!to!be!defined!using!a!panel!of!neutralising!mAbs![366],!






One! issue! with! the! murine! genital! C.) trachomatis! challenge! model! that! we!
encountered!was!that!the!mice!did!not!have!long!enough!infection!periods!to!assess!
any! late! acting! immune! responses.! With! naïve! mice! clearing! the! C.) trachomatis!
genital! infection,! it! leaves!only!three!days!post!chlamydial! infection!where!one!can!
confidently!observe!any!significant!chlamydial!load!reduction!due!to!vaccination.!The!
use!of!C.)muridarum!as!the!challenge!species!could!avoid!this!issue.!The!intravaginal!
inoculation!of!C.)muridarum! in!mice! results! in! a! genital! tract! infection! that! closely!
resembles! acute! genital! C.) trachomatis! infections! in! women,! with! mice! generally!
resolving!the!genital!tract!infection!within!4!weeks![120].!The!use!of!C.)muridarum!as!
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the! challenge! species! may! provide! a! longer! sampling! window! to! investigate!
differences!in!shedding!loads!between!vaccinated!and!unvaccinated!mice!but!would!




into! immunogenicity! and! intravaginal! C.) trachomatis! challenge! studies! in!
cynomolgus! macaques! (Macaca) fascicularis)! by! the! ADITEC! Consortium.! Several!
species! of! nonhuman! primates! (marmoset! [368],! grivet! [369],! baboon! [370])! have!
previously!been!used!as!models!for!genital!C.)trachomatis!infections,!with!the!most!
frequently! used! model! being! the! pig.tailed! macaque! (Macaca) nemestrina)!!
developed! by! Patton! et) al.! [371,! 372].! Macaques! have! a! similar! anatomy! and!
physiology! to! the! female! reproductive! tract! of! humans,! with! a! similar! 28.30.day!
menstrual! cycle! and! similar! vaginal! microflora! [135].! ! They! are! also! naturally!
susceptible! to! genital! tract! infection!with!human!biovars!of!C.) trachomatis! and!do!
not! need! hormonal! pretreatment! to! influence! the! infection! [136].! In! the! in) situ)
model,!macaques!are!infected!with!C.)trachomatis!by!cervical!inoculation,!producing!
cervicitis! and! salpingitis! [373]! [374],! with! repeated! salpingeal! infections! causing!
tubal! scarring! and! distal! tubal! obstruction! –! similar! to! the! development! of! pelvic!









of!MOMP.specific!antibodies!were! transfused.!This!would!be! tested!by! transfusing!
higher!concentrations!of!MOMP.specific!DAMP!sera!from!concentrating!the!MOMP.
specific!antibodies!from!multiple!DAMP!vaccinated!mice.!The!antibodies!induced!by!
the! DAMP! regimen! could! be! further! characterised! in! functional! experiments!
including! transwell! assays! to!assess!antibody.mediated!phagocytosis!or! chromium.
51!release!assays!to!assess!ADCC!potential.!!
As!well!as! these,! further!optimisation!of! the!murine!ocular!sampling!model! should!
be!carried!out.!We!have!used!the!ocular!sampling!method!to!assess!antibody!type!
and!their!concentrations,!yet!this!same!procedure!could!be!used!to!assess!cytokine!









An! efficacious! vaccine! for!Chlamydia) trachomatis! would! have! an! enormous! public!
health! impact.! Infection.induced! immunity! in! both! animal! models! and! humans!
suggests!a! strong! role! for!CD4+!Th1.biased! immune! responses.!Work! in! this! thesis!
described! the! utility! of! DNA,! HuAd5,! MVA! and! recombinant! protein! vaccines! in!
heterologous! prime.boost! vaccine! regimens! to! elicit! an! array! of! MOMP.specific!
immune! responses,! following! which! the! protection! of! genital! C.) trachomatis!
infection! was! assessed.! The! DAMP! regimen,! which! induced! a! significantly! greater!
MOMP.specific! IgG2a:IgG1!ratio!than!any!other! investigated!regimen,!was!the!only!
regimen! to! significantly! reduce! genital! C.) trachomatis! loads! below! that! of!
unvaccinated!control!mice.!This!protection!was!shown!to!be!CD4+!T!cell!mediated.!
The!vaccines!constructed!within!this!thesis!and!their!use! in!the!DAMP!regimen!are!
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Size Distribution by Number
Record 28: trachomatis D EBs 10^-2 1 Record 29: trachomatis D EBs 10^-2 2
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ATGAAGAAGCTGCTGAAGAGCGTGCTGGTGTTCGCCGCCCTGAGCAGCGCCAGCAGCCTG
CAGGCCCTGCCCGTGGGCAACCCCGCCGAGCCCAGCCTGATGATCGACGGCATCCTGTGGG
AGGGCTTCGGCGGCGACCCCTGCGACCCCTGCACCACCTGGTGCGACGCCATCAGCATGCG
CATGGGCTACTACGGCGACTTCGTGTTCGACCGCGTGCTGAAGACCGACGTGAACAAGGA
GTTCCAGATGGGCGACAAGCCCACCAGCACCACCGGCAACGCCACCGCCCCCACCACCCTG
ACCGCCCGCGAGAACCCCGCCTACGGCCGCCACATGCAGGACGCCGAGATGTTCACCAACG
CCGCCTGCATGGCCCTGAACATCTGGGACCGCTTCGACGTGTTCTGCACCCTGGGCGCCAG
CAGCGGCTACCTGAAGGGCAACAGCGCCAGCTTCAACCTGGTGGGCCTGTTCGGCGACAAC
GAGAACCAGAGCACCGTGAAGACCAACAGCGTGCCCAACATGAGCCTGGACCAGAGCGTG
GTGGAGCTGTACACCGACACCGCCTTCAGCTGGAGCGTGGGCGCCCGCGCCGCCCTGTGG
GAGTGCGGCTGCGCCACCCTGGGCGCCAGCTTCCAGTACGCCCAGAGCAAGCCCAAGGTG
GAGGAGCTGAACGTGCTGTGCAACGCCGCCGAGTTCACCATCAACAAGCCCAAGGGCTAC
GTGGGCCAGGAGTTCCCCCTGGCCCTGATCGCCGGCACCGACGCCGCCACCGGCACCAAG
GACGCCAGCATCGACTACCACGAGTGGCAGGCCAGCCTGGCCCTGAGCTACCGCCTGAACA
TGTTCACCCCCTACATCGGCGTGAAGTGGAGCCGCGCCAGCTTCGACGCCGACACCATCCG
CATCGCCCAGCCCAAGAGCGCCACCGCCATCTTCGACACCACCACCCTGAACCCCACCATCG
CCGGCGCCGGCGACGTGAAGGCCAGCGCCGAGGGCCAGCTGGGCGACACCATGCAGATC
GTGAGCCTGCAGCTGAACAAGATGAAGAGCCGCAAGAGCTGCGGCATCGCCGTGGGCACC
ACCATCGTGGACGCCGACAAGTACGCCGTGACCGTGGAGACCCGCCTGATCGACGAGCGC
GCCGCCCACGTGAACGCCCAGTTCCGCTTCTAATAA!
Figure!9.6!Human!codon!optimised!nucleotide!sequence!of!consensus!MOMP.!!!
!
!
MKKLLKSVLVFAALSSASSLQALPVGNPAEPSLMIDGILWEGFGGDPCDPCTTWCDAISMRMG
YYGDFVFDRVLKTDVNKEFQMGDKPTSTTGNATAPTTLTARENPAYGRHMQDAEMFTNAAC
MALNIWDRFDVFCTLGASSGYLKGNSASFNLVGLFGDNENQSTVKTNSVPNMSLDQSVVELYT
DTAFSWSVGARAALWECGCATLGASFQYAQSKPKVEELNVLCNAAEFTINKPKGYVGQEFPLA
LIAGTDAATGTKDASIDYHEWQASLALSYRLNMFTPYIGVKWSRASFDADTIRIAQPKSATAIFD
TTTLNPTIAGAGDVKASAEGQLGDTMQIVSLQLNKMKSRKSCGIAVGTTIVDADKYAVTVETRLI
DERAAHVNAQFRF**!
Figure!9.7!Amino!acid!sequence!of!consensus!MOMP.!
